The evolution and adaptation of clinical <i>Pseudomonas aeruginosa</i> isolates from early cystic fibrosis infections by Lindegaard, Mikkel
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
The evolution and adaptation of clinical Pseudomonas aeruginosa isolates from early
cystic fibrosis infections
Lindegaard, Mikkel; Long, Katherine; Molin, Søren; Johansen, Helle Krogh
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Lindegaard, M., Long, K., Molin, S., & Johansen, H. K. (2016). The evolution and adaptation of clinical
Pseudomonas aeruginosa isolates from early cystic fibrosis infections. Lyngby: Novo Nordisk Foundation Center
for Biosustainability.
  
 
 
The evolution and adaptation of clinical 
Pseudomonas aeruginosa isolates from 
early cystic fibrosis infections 
 
 
PhD-thesis 
 
Mikkel Lindegaard 
 
Novo Nordisk Foundation Center for Biosustainability 
Technical University of Denmark 
 
 
September, 2016  
  
 
 
 
 
 
 
 
 
The evolution and adaptation of clinical Pseudomonas aeruginosa 
isolates from early cystic fibrosis infections 
 
PhD thesis written by Mikkel Lindegaard  
Main supervisor Katherine S. Long 
Co-supervisor Søren Molin 
Co-supervisor Helle Krogh Johansen 
 
 
© PhD Thesis 2016 Mikkel Lindegaard 
Novo Nordisk Foundation Center for Biosustainability 
Technical University of Denmark 
Building 220, Kemitorvet 
2800 Kgs. Lyngby, Denmark  
 
 
  
  
i 
 
Preface 
This thesis was written as a partial fulfilment of the requirements to 
obtain a PhD-degree at the Technical University of Denmark. The work 
presented here was performed between June 2013 and September 2016 at 
the Novo Nordisk Foundation Center for Biosustainability, Technical 
University of Denmark (DTU). The work was supervised by Katherine 
S. Long, Associate Professor at DTU, Søren Molin, Professor at DTU 
Bioengineering at DTU, and Helle Krogh Johansen, DMSc, Chief 
Physician at Rigshospitalet, Copenhagen. The work was financed by 
DTU. 
 
The thesis was evaluated by Professor Lars Jelsbak from DTU, 
Professor Hanne Ingmer from the University of Copenhagen, and 
Professor Dr. Susanne Häußler, Head of the Department Molecular 
Bacteriology at Helmholtz Centre for Infection Research, Germany. 
 
 
 
 
 
Mikkel Lindegaard 
Kgs. Lyngby, September 2016 
  
ii 
 
Abstract 
Pseudomonas aeruginosa is a major cause of morbidity and mortality 
in cystic fibrosis (CF) patients. P. aeruginosa infects the CF airways and 
establishes chronic infections that can last for a lifetime during which P. 
aeruginosa evolves in order to adapt to the environment.  
 
In this PhD thesis, we investigated the evolution of two convergent 
lineages of P. aeruginosa isolated from the early stages of infection in 
two CF patients using both transcriptomic and proteomic methods. Both 
lineages harbour sequential mutations in a specific regulatory system, the 
retS-gacS-gacA-rsmA-rsmYZ signalling pathway, which reciprocally 
regulates the expression of genes attributed to chronic and acute 
infection states. Additionally, we investigate the effects of the evolution 
not caused by the mutations in this regulatory system through allelic 
replacements in the clinical isolates. 
 
We show that the initial stages of infection with P. aeruginosa is 
subject to temporal and differential expression of virulence factors 
caused by mutations in the retS-gacS-gacA-rsmA-rsmYZ signalling 
pathway. Initially, a mutation in retS causes a switch to a chronic 
infection mode characterised by the expression of the Type VI secretion 
system (T6SS) and induction of the phenazine biosynthesis operons. The 
effects of the retS-mutation are reversed with a later mutation in either 
gacS or gacA, which lowers the expression of the T6SS and the 
phenazine biosynthesis operons and instead leads to high expression of 
the Type III secretion system (T3SS). This suggests that the current 
dogma of this regulatory system does not adequately explain the 
biological significance of this system, as the opposite mutation pattern 
would be expected if this dogma were true. Furthermore, we show that 
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the residual evolution caused by other mutations also has an effect on the 
expression of virulence factors. 
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Dansk resumé 
Pseudomonas aeruginosa er en stor årsag til morbiditet og dødelighed i 
cystisk fibrose (CF) patienter. P. aeruginosa forårsager infektioner i CF 
luftvejene og etablerer kroniske infektioner, der kan vare en 
menneskealder. I denne tid udvikler P. aeruginosa sig for at tilpasse sig 
til miljøet ved at tilegne sig mutationer. 
 
I denne Ph.d.-tese undersøgte vi evolutionen af to konvergerende 
klontyper af P. aeruginosa, der var isoleret fra de tidlige stadier af 
infektion i to CF patienter ved brug af transkriptom- og proteommetoder. 
Begge klontyper har sekventielle mutationer i et specifikt regulatorisk 
system, retS-gacS-gacA-rsmA-rsmYZ signalsystemet, der reciprokt 
regulerer ekspressionen af gener tillagt betydning for enten kroniske 
infektionstilstande eller akutte infektionstilstande. Endvidere undersøger 
vi effekterne af evolutionen, der ikke er forårsaget af mutation i dette 
regulatoriske system ved brug af alleludskiftninger i de kliniske isolater. 
 
Vi viser, at de første stadier af infektion med P. aeruginosa er omfattet 
af temporal og differentielt udtryk af virulensfaktorer forårsaget af 
mutationer i retS-gacS-gacA-rsmA-rsmYZ signalsystemet. Først opstår en 
mutation i retS, hvilket giver et skift til kronisk infektionstilstand 
karakteriseret ved genudtryk af Type 6 Sekretionssystem (T6SS) og 
inducering af phenazin-biosynteseoperonerne. Virkningen af mutationen 
i retS bliver omgjort af en mutation i enten gacS eller gacA, hvilket 
sænker genudtrykket af T6SS og phenazin-biosynteseoperonerne og i 
stedet fører til højt genudtryk af Type III sekretionssystemet (T3SS). 
Dette antyder, at det nuværende dogme om dette regulatoriske system 
ikke på tilfredsstillende vis beskriver den biologiske signifikans af dette 
system, da the modsatte mutationsmønster ville være forventet, hvis 
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dette dogme var sandt. Endvidere viser vi, at den overskydende 
evolution, forårsaget af andre mutationer, også har en indflydelse på 
genudtrykket af virulensfaktorer.  
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Introduction and thesis outline 
Pseudomonas aeruginosa is a major cause of morbidity and mortality 
in cystic fibrosis (CF) airway infections. It has the ability to establish 
chronic infections that are difficult to eradicate. This leads to lifelong 
infections, giving the bacteria ample time to evolve and adapt to the CF 
airways. The advent of next-generation sequencing (NGS) has given 
unprecedented insight into how P. aeruginosa evolves in the CF airways 
and has shown that regulatory networks are often the targets of mutations 
causing major changes in the physiology of the bacterium. Especially the 
early stages of the infections are characterised by positive selection of 
mutations, meaning that the mutations that occur are improving the 
fitness of the bacteria. However, the evolution is a complex process with 
a multitude of mutations in genes involved in anything from metabolism 
to virulence. Furthermore, many regulatory systems are interconnected 
and thus the occurrence and combination of mutations can lead to 
unexpected results.  
The aim of this thesis was to investigate the early adaptation and 
evolution of clinical P. aeruginosa isolates from CF infections. To this 
end, we investigate two lineages from the CF airways that have 
mutations in retS-gacS-gacA-rsmA-rsmYZ signalling pathway alongside 
many other mutations. This specific regulatory system serves as a switch 
between the expression of genes attributed to acute and chronic infection 
states.  
This thesis contains three introductory sections. Section 1 is an 
introduction to P. aeruginosa as a bacterium emphasising its versatility 
with a special focus on the impressive arsenal of elements involved in 
virulence, as some of them are regulated by this specific regulatory 
network. This is followed by an introduction to the evolution of P. 
aeruginosa in the CF airways. 
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Section 2 gives an introduction to regulation in P. aeruginosa. The 
functions of σ-factors, two-component systems (TCSs), and small RNAs 
(sRNAs) are explained with select examples that aim to give an idea of 
the complex regulatory circuits at play. Special focus is given to the retS-
gacS-gacA-rsmA-rsmYZ signaling pathway as it was the subject of study 
in this thesis. 
Section 3 gives the historical background of how this PhD-thesis was 
conceived and its relevance to the research on the evolution and 
adaptation of P. aeruginosa in CF airway infections. The studies that led 
to the ideas of this project are presented and the rationale behind the 
research is explained. 
This is followed by section 4, where the conclusions of this thesis are 
given and future perspectives of what should be investigated next are 
presented. 
Attached are the manuscripts that are the results of the work performed 
during this PhD.  
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1. Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a motile, Gram-negative, and rod-shaped 
bacterium, belonging to the genus Pseudomonas. The pseudomonads are 
found in a broad range of environments such as soil and marine 
environments [1], but also in association with plants and animals. P. 
aeruginosa is the most studied of the genus due to it being an 
opportunistic pathogen to humans and other mammals, unlike most other 
members of the Pseudomonas genus. Multi-drug resistant P. aeruginosa 
were in 2013 named as a serious threat due to the emergence of strains 
resistant to the majority of antibiotics, including aminoglycosides, 
cephalosporins, fluoroquinolones, and carbapenems [2]. 
P. aeruginosa is a common cause of nosocomial infections in burn 
wound patients, in mechanically ventilated patients, and the 
immunosuppressed patients, such as AIDS, cystic fibrosis (CF) and 
cancer patients [3], due to its ability to create biofilms, its many 
virulence factors, its innate antibiotic resistance, and its ability to thrive 
in a vast array of environments.  
 
1.1. Genome characteristics 
The first whole-genome sequenced P. aeruginosa was PAO1, the most 
common laboratory strain and originally a wound isolate. The genome 
was published in 2000 [4] and has a size of 6.3 Mbp, a GC-content of 
66.6% and was the largest bacterial genome sequenced at the time. A 
high proportion (~8%) of its 5570 predicted open reading frames (ORFs) 
are predicted to encode either transcriptional regulators or two-
component systems. Since the release of the first genome, many more 
strains have been sequenced with the Pseudomonas Genome Database 
[5] now containing 50 complete genomes and about 1500 unfinished 
genomes. The genome size ranges from 5.5 to 7 Mbp [6]. 
4 
 
The P. aeruginosa pan-genome, which represents the entire gene set of 
all strains of the species, includes at least 9344 genes [7] of which 5233 
are shared between all P. aeruginosa species (core genome) and the rest 
represents the genes present only in some strains (accessory genome). 
Therefore P. aeruginosa, as a species, contains considerable genomic 
diversity between the strains. As part of the accessory genome, some 
strains contain a variety of pathogenicity islands and genomic islands 
that can contain genes encoding toxins, adhesins, integrases, 
transposases, antibiotic and heavy metal resistance genes, making these 
strains considerably more virulent or capable of surviving in hostile 
environments than strains lacking these [8], [9].  
 
1.2. Metabolism 
P. aeruginosa displays a versatile metabolism like many other 
members of the Pseudomonas genus. Some pseudomonads are capable 
of growing on more than 100 different simple and complex compounds 
as carbon and energy sources, owing to their remarkable metabolic 
diversity [10, pp. 413–415]. 
The preferred carbon and nitrogen sources of P. aeruginosa include 
short-chain fatty acids, amino acids, carboxylic acids, and polyamines, 
but the bacterium is also capable of catabolizing sugars through the 
Entner-Doudoroff pathway [11]. In the presence of multiple substrates, 
P. aeruginosa makes use of carbon catabolite repression control in order 
to uptake and metabolise the preferred carbon sources first [12]. 
Furthermore, the ability of P. aeruginosa to grow on n-alkanes and 
halogenated aromatic compounds as sole carbon sources, demonstrates 
the capability of the bacterium to degrade complex xenobiotics [13], 
[14].  
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Energy generation occurs mainly by oxidative phosphorylation, but 
depending on conditions P. aeruginosa will also grow as a facultative 
anaerobe using alternative electron acceptors such as nitrate through 
denitrification, or through fermentation of arginine and pyruvate. The 
genes encoding aerobic respiration, denitrification, and anaerobic 
fermentation have so far been identified in all strains of P. aeruginosa, 
i.e. as part of the core genome, emphasizing that the metabolic versatility 
is important to the lifestyle of P. aeruginosa in general [7]. 
 
1.3. Key elements for virulence 
Virulence factors are traits of a bacterium that enable it to establish 
infection or otherwise be virulent. P. aeruginosa has a formidable array 
of virulence factors available to it, including at least five secretion 
systems [15], [16] (Figure 1), many iron uptake systems, the ability to 
form biofilms, secondary metabolites, and intrinsic antibiotic resistance. 
The combination of these traits enables P. aeruginosa to establish 
infections. 
 
1.3.1. Secretion systems 
Secretion systems are proteins or protein-complexes that allow for the 
secretion of effector molecules, such as toxins, but also proteins that can 
degrade the environment, such as elastases, lipases, and proteases, in 
order to release otherwise unavailable nutrients. Some systems work by 
simply secreting the effector molecules into the environment, while 
others actively inject the effectors into other cells. 
The type I secretion systems (T1SS) (apr/has-genes) are simple 
secretion systems that require three components to function; an outer-
membrane protein, an inner-membrane ATP-binding cassette (ABC) 
transporter, and an adaptor connecting the two in the periplasm [17]. At 
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least three proteins are secreted through these systems [18], AprA, an 
alkaline protease, AprX, a protein of unknown function, and HasAp, a 
haem acquisition protein. AprA is capable of degrading collagen, the 
main structural protein in connective tissues [19]. It has been suggested 
that HasAp is especially important during the early stages of infection, 
where iron is scarce as it is capable of acquiring iron through haem from 
haemoglobin [15].  
The type II secretion systems (T2SS) (xcp-genes/hxc-genes) are very 
versatile systems. The T2SS Xcp can secrete at least 14 proteins with 
different functions such as proteases and lipases, but the Hxc secretes 
only one protein, LapA, an alkaline phosphatase [20]. The two systems 
seem to be divergent systems that exist in their own clusters consisting of 
11 genes in two different loci. A key difference from the T1SS, is that 
the outer porin is a 12-subunit multimer allowing for even folded 
exoproteins to pass through [15]. Secreted proteins include LasB, an 
elastase, which efficiently degrades elastin, a major component of 
connective tissue [21] of the lungs, suggesting a key function in the 
infection of the airways. Lipases and phospholipases, such as LipA, 
LipC, PlcH, and PlcN, have been shown to degrade lung surfactants, but 
also modify immune function [22], [23]. The exotoxin A, ToxA, 
inactivates the eukaryotic elongation factor-2 by ADP-ribosylation, 
thereby halting protein synthesis in the host cell, leading to cell death 
[24]. 
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Figure 1. The secretion systems of P. aeruginosa showing the different 
modes of action used. The T1SS secretes effector compounds directly 
into the extracellular medium. The T2SS and the T5SS make use of the 
Tat and Sec secretion pathway, respectively, to export effector 
compounds to the periplasm and then secrete effector compounds 
through their own machinery. The T3SS and the T6SS secrete effector 
compounds directly from the cytoplasm to the target through needle-like 
complexes. Adapted from Bleves, et al., 2010 [15]. 
 
The type III secretion system (T3SS) is different from the T1SS and 
T2SS as it forms a needle-like complex, which helps in injecting effector 
proteins directly into target cells. This requires a certain degree of 
complexity and the system consists of 35 clustered genes organized into 
five operons. The needle-like complex delivers a set of proteins to the 
target cell membrane that then forms a pore, enabling delivery of effector 
proteins. At least four effector proteins are injected through this system, 
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namely ExoS, ExoT, ExoU, and ExoY. ExoS and ExoT are both ADP-
ribosyltransferases, like ToxA [25], [26], but unlike ToxA, do not target 
protein synthesis. Their roles are not fully understood, but they seem to 
target host signalling pathways, specifically through ADP-ribosylation of 
Ras, affecting host-cell function, decreasing phagocytosis, and increasing 
dissemination of P. aeruginosa [27]–[30]. ExoY is an adenylate cyclase 
that impairs the ability of endothelial cell proliferation and vascular 
repair following lung injury [31]. ExoU is a phospholipase with broad 
substrate specificity causing tissue destruction and localized 
immunosuppression [32], [33]. Curiously, all of the four toxins are not 
present in most strains of P. aeruginosa. In fact, the toxins seem to be 
paired up, where ExoU and ExoT are commonly found together and 
likewise for ExoS and ExoT [32].  
The type V secretion systems (T5SS) are the simplest of them all, 
consisting of either one protein with two domains, the autotransporters, 
or two proteins, the two partner secretion systems, where the domains 
are encoded separately on the genome. The proteins are transported to 
the outer face of the outer membrane, where they either remain, or are 
released through proteolytic cleavage [15], [16]. They encode a variety 
of toxins. EstA is an autotransporter esterase, which sits on the outer face 
of the outer membrane. It has been shown to be important for 
rhamnolipid production, which in turn affects cellular motility and 
biofilm formation [34]. LepA/LepB, a two partner secretion system, 
secretes a protease that has been suggested to modulate the host response 
to bacterial infection [35]. CdrA/CdrB, also a two partner secretion 
system, is responsible for the transport of CdrA, an adhesin, to the outer 
membrane, which has been found to promote biofilm formation and 
auto-aggregation in liquid culture [36], [37]. PlpD is a lipolytic enzyme 
and the function is not well characterised. However, PlpD shows 
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homology with the ExoU of the T3SS, suggesting immunomodulatory 
function [38]. 
The Type VI secretion system (T6SS) is encoded in three loci in the P. 
aeruginosa PAO1 genome, and is the most recently discovered of the 
secretion systems. Similarly to the T3SS, it injects effector proteins into 
competing cells. The three T6SSs (HI, HII, and HIII) have distinct 
evolutionary histories, are regulated by different mechanisms suggesting 
different functions [39], and are thought to have originated from 
bacteriophages. At least six effector proteins (Tse1-6) are secreted 
through the T6SS, and they are encoded next to their cognate immunity 
proteins (Tsi1-6) that give immunity to the effector proteins. Tse2 has 
been found to arrest the growth of both prokaryotic and eukaryotic cells 
lacking the immunity protein, Tsi2 [40]. Tse1 and Tse3 are injected into 
the periplasm and hydrolyse peptidoglycan leading to cell lysis of 
bacteria lacking the immunity proteins, Tsi1 and Tsi3 [41]. Tse4-6 also 
function as antibacterial effectors, but Tse5 and Tse6 were found to 
inhibit Escherichia coli growth even if E. coli also expressed the cognate 
immunity protein, whereas the same was not observed in P. aeruginosa 
[42], suggesting that the immunity proteins are not sufficient to provide 
immunity to the effector proteins. 
 
1.3.2. Secondary metabolites 
P. aeruginosa produces a number of secondary metabolites that give 
an advantage in the environment and affect both prokaryotic and 
eukaryotic cells negatively either through inhibition of growth or cell-
death. Examples are given below. 
Pyocyanin is one of the typical secondary metabolites produced by P. 
aeruginosa and it belongs to the class of phenazines. The genes required 
for the production of pyocyanin are encoded by two operons, 
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phzA1B1C1D1E1F1G1 and phzA2B2C2D2E2F2G2, and two single 
genes, phzM and phzS, which are encoded next to either operon. The 
phzM and phzS gene products are responsible for the final conversion 
into pyocyanin [43]. In laboratory culture, pyocyanin is easily 
recognisable in high concentrations as it is blue in its oxidised state, 
usually giving the growth medium a green-blue colour. Pyocyanin is a 
redox-active compound and is capable of causing intracellular oxidative 
stress by crossing host cell membranes and generating reactive oxygen 
species (ROS), superoxide (O2·-) and hydrogen peroxide (H2O2) [44], 
[45]. This can result in cellular damage, also increasing inflammation, 
and cell-death [46]. Furthermore, pyocyanin inhibits the growth of 
competing bacteria through similar mechanisms [47].  
P. aeruginosa is also capable of producing another secondary 
metabolite, hydrogen cyanide (HCN). The genes encoding the HCN 
synthase are encoded in an operon, hcnABC. It is produced under high 
cell densities and decreased oxygen availability, but not anoxic 
conditions. Furthermore, maximum production occurs between 34 °C 
and 37 °C [48], suggesting that HCN is important in infection scenarios. 
HCN has been shown to be able to kill competing bacteria both directly 
[49], and indirectly, through increasing the susceptibility of other 
bacteria to antibiotics by inhibiting cytochrome oxidase-dependent efflux 
pumps [50]. Furthermore, HCN shows toxicity towards host cells as it 
acts as a cellular asphyxiant. CN- ions are non-competitive inhibitors as 
they are able to bind to Fe3+ in haem, which in turn binds to cytochrome 
c oxidase, an important component in the respiratory chain of 
mitochondria, thus preventing oxygen from binding [51], [52]. 
Interestingly, P. aeruginosa can protect itself against this effect by using 
a cyanide-insensitive oxidase [53]. 
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1.3.3. Iron uptake 
In infection settings, most iron will be sequestered by host haem 
molecules, part of the host aerobic respiration, and is thus not available 
for uptake. For this reason, P. aeruginosa has multiple iron uptake 
systems suited for different purposes depending on the availability and 
the oxidation state of the iron [54], [55]. 
Pyoverdine and pyochelin, also secondary metabolites, are two 
siderophores capable of chelating Fe3+. P. aeruginosa secretes 
siderophores, which are then taken up by specific receptors. The genes 
responsible for the production of pyoverdine are encoded by the 14 pvd 
genes [56], whereas the genes for production of pyochelin are encoded in 
two operons, pchDBCA and pchEFGHI [57], [58]. Pyoverdines are high-
affinity siderophores and are essential for virulence in acute infection 
models [59]. Pyochelins have lower affinity for iron and seem to be 
favoured for iron acquisition unless iron limitation is severe [60]. The 
energy-transducing protein, TonB, is essential as it is required for the 
reuptake of the siderophores after binding iron by signalling for and 
mediating transport through other receptor proteins [61], [62]. 
Additionally, P. aeruginosa also has systems (Phu and Hap) for 
acquiring iron by taking up haem or haem-containing  proteins [63]. The 
Phu system directly extracts haem using a TonB-dependent receptor, 
whereas the Has-system secretes a haemophore that binds to haem, and 
the complex is then taken up by another TonB-dependent receptor [54].  
In the case of bacterial competition for iron, P. aeruginosa is also 
capable of taking up xenosiderophores, i.e. siderophores from other 
bacteria and fungi, through a number of TonB-dependent receptors [64].  
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1.3.4. Biofilm formation capabilities 
P. aeruginosa is capable of forming biofilms, which are communities 
of bacteria embedded in extracellular polymeric substances [65], [66]. 
Bacteria in biofilms are resistant to antibiotics, phagocytosis, and 
surfactants and biofilms are difficult to remove once established [67]. P. 
aeruginosa has several systems to produce the extracellular substances 
composing the biofilm, such as exopolysaccharides and extracellular 
DNA [68]. The lifestyle of P. aeruginosa in biofilms is shown in Figure 
2. 
 
Figure 2. Developmental cycle of P. aeruginosa in biofilms. 1) The 
bacteria attach to a surface. 2) Through cell division, expression of 
biofilm genes, and adherence of other cells, a microcolony forms. 3) 
Continued growth of the biofilm. Subpopulations develop due to 
quorum-sensing and nutrient gradients within the biofilm. 4) Some cells 
become motile and disperse due to quorum-sensing, external cues, and 
physical disruption. The dispersing bacteria can then repeat the cycle. 
Adapted from Taylor, et al., 2014 [69]. 
 
The Psl system, encoded by the psl-operon, which contains 15 genes 
from pslA to pslO, is a major contributor to biofilm formation and leads 
to enhanced cell-surface and intercellular adhesion in P. aeruginosa [70]. 
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When the Psl system is active the biofilm is rich in galactose and 
mannose [71]. Pel is another biofilm formation system, but its role in 
biofilm formation is less understood. It is encoded by a six gene operon, 
pelABCDEF, and when active a matrix rich on glucose, sensitive to 
cellulase, is created [72]. Extracellular DNA is also a key structural 
component in biofilms and helps in the formation of the characteristic 
mushroom shapes that are present in mature biofilms. The DNA seems to 
be random chromosomal DNA [73].  
Alginate is another component of biofilms produced by the gene 
products of the alg-genes. The overproduction of alginate leads to the 
well-known mucoid phenotype, a common hallmark of chronic 
infections [74]. Alginate has functions in persistence, immunoevasion, 
and protects bacteria in the matrix from free radicals from the immune 
system [75]. 
 
1.3.5. RND efflux pumps 
While not a de facto virulence factor, the intrinsic and acquired 
resistance of P. aeruginosa to many antibiotics is important for its ability 
to establish infections and cause disease in humans and animals as it will 
often resist treatment by antibiotics [76]. The PAO1 genome encodes 
multiple efflux pumps of the resistance-nodulation-division (RND) type 
(Figure 3). However, P. aeruginosa is also able to acquire plasmids 
encoding genes for resistance to antibiotics that it is not intrinsically 
resistant to, leading to clones resistant to virtually all clinically relevant 
antibiotics [77]. The four most important RND efflux pumps are 
MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY [78]–[80]. 
The pumps consist of three components; an efflux transporter in the 
inner membrane, an outer membrane channel, and an accessory protein 
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connecting the two in the periplasm [81]. RND efflux pumps often have 
broad substrate specificity that is not limited to antibiotics (Table 1).  
 
Figure 3. The structure of the AcrAB-TolC RND efflux pump in E. 
coli. It is homologous to the MexAB-OprM in P. aeruginosa. 
AcrB/MexB is inserted into the cytoplasmic membrane and is 
responsible for substrate recognition. AcrA/MexA is the accessory 
protein that connects AcrB/MexB to the outer membrane channel. 
TolC/OprM is the outer membrane channel [82]. Adapted from Blair 
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and Piddock, 2009 [83]. 
 
Table 1. The most important RND efflux pumps of P. aeruginosa and 
their antibiotic substrates. AG: aminoglycosides, BL: β-lactams, CM: 
chloramphenicol, CP: cephalosporins, FQ: fluoroquinolones, ML: 
macrolides, NB: novobiocin, TC: tetracycline, TI: tigecycline, TM: 
trimethoprim, ZBL: zwitterioninc β-lactams. Adapted from Li, et al., 
1997 [84]. 
Efflux pump Antibiotic 
resistance provided 
References 
MexAB-OprM AG, BL, CM, ML, 
NB, TC, TM 
[85]–[87] 
MexCD-OprJ CM, CP, FQ, TC [88]–[90] 
MexEF-OprN CM, FQ [91], [92] 
MexXY AG, FQ, ML, TC, 
TI, ZBL 
[93], [94] 
 
 
1.4. P. aeruginosa in cystic fibrosis 
P. aeruginosa is the major pathogen of CF patients, leading to 
significant morbidity and mortality for patients by causing chronic lung 
infections [95]. 
 
1.4.1. Cystic fibrosis 
CF is a genetically inherited recessive disorder in humans caused by 
mutations in the cystic fibrosis transmembrane regulator (CFTR) gene 
leading to a faulty protein, which results in defective chloride ion 
transport across epithelial cell surfaces [96]. This causes dehydration of 
the mucous in the airways, leading to reduced or defective mucociliary 
clearance and thus chronic infection with bacteria and fungi despite 
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heavy treatment with antibiotics [97]. The chronic infections result in a 
state of constant inflammation, permanent remodelling of the airways 
and decreased lung function  [98]. CF patients also suffer from poor food 
digestion and nutrient absorption, which is treated with pancreatic 
enzyme replacement therapy [99]. The end result is usually respiratory 
failure and lung transplantation or death. Before the development of 
extensive treatment programs, patients would die at a young age due to 
lung infections [100]. However, a newborn with CF can expect to live 
upwards of 50 years [101]. CF is most common in people of Northern 
European descent with an incidence of around 1 in 3000 [102]. In 
contrast, it occurs in 1 of 350000 people of Japanese descent [103].  
The infections of the CF airways are caused by many different species 
such as P. aeruginosa, Burkholderia cepacia, Staphylococcus aureus, 
Haemophilus influenzae, Achromobacter xylosoxidans, 
Stenotrophomonos maltophilia and others [104] (Figure 4). Of special 
interest are the first three organisms mentioned, due to their high 
incidence in CF airway infections. At the Copenhagen Cystic Fibrosis 
Center in Denmark, a large number of clinical isolates of P. aeruginosa 
have been collected and stored longitudinally from CF patients, 
providing a detailed picture of how these strains evolve and adapt to the 
CF environment in both early and late stages of infection [105]–[107]. 
The isolates studied in this thesis are part of this collection. 
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Figure 4. The prevalence of different pathogens in CF patients with 
the patients age. P. aeruginosa becomes the dominant microorganism 
in the mid-twenties. Adapted from Folkesson, et al., 2012 [95] 
 
1.4.2. Evolution of P. aeruginosa in CF 
Due to the long term infections of P. aeruginosa in the CF airways, the 
bacteria have ample time to evolve and adapt to the new environment 
[108]. The CF sputum is a complex medium that allows bacteria to thrive 
since they are not cleared by the normal mucociliary mechanism.  
The selective pressures of the CF airways are not well-understood, but 
can be presumed to consist of changes in available nutrients, the host 
defence mechanisms, other microbes, antibiotics, and oxidative and 
nitrosative stress [108]. The CF sputum is a nutritionally rich growth 
medium for bacteria and supports bacterial growth to high cell densities 
(>109 cells/mL sputum) [109]. The advent of NGS has enabled the 
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detection of single-point mutations in evolving P. aeruginosa. Studies 
have shown signs of convergent evolution reviewed in Winstanley, et al., 
2016 [108]. Mutations have been found in genes related to virulence 
(attenuation), quorum sensing, motility, iron acquisition, antibiotic 
resistance (increase), biofilm formation and mucoidy, metabolism 
(auxotrophy), and transport of small molecules. In particular, mutations 
are found in regulators, leading to potential large-scale phenotypic 
changes. 
P. aeruginosa shows diversification during infection of the CF 
airways. However, evolution and adaptation have mostly been studied 
using single isolates [110]. It has been shown that different parts of the 
lungs can have different populations of P. aeruginosa, but also that the 
lungs are usually dominated by a single lineage [111]. A single isolate 
from a sputum sample will accurately represent the population of that 
sputum sample [110].  
 
1.4.3. Model systems of CF 
A major issue in studying the behaviour of P. aeruginosa and other 
bacteria in CF airway infections is the difficulty in recreating the 
conditions of the infection environment, which can have marked 
influence on the phenotype of the bacteria [112], [113]. Animal models 
have proven difficult as they have thus far not been able to accurately 
depict the long term infection observed in humans due to differences in 
the manifestation of mutations in the CFTR gene between species [114]. 
Different versions of media have been composed to mimic the 
composition of the CF sputum. Two of them are artificial sputum 
medium (ASM) [112] and synthetic CF sputum medium (SCFM) [113]. 
They are both based on detailed analyses of the available amino acids, 
salts, ions, and sugars available in the CF sputum. Furthermore, ASM 
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also contains mucin and DNA, which creates a viscous mixture to further 
mimic the CF sputum. Interestingly, in both media formation of 
microcolonies in the form of small aggregates of bacteria occurs. This is 
thought to be the growth mode of P. aeruginosa in the oxygen-limited 
CF airways [115].  
 
In conclusion, the metabolic versatility of P. aeruginosa combined 
with its wide array of secretion systems, secondary metabolites, biofilm 
formation capabilities, iron uptake systems and innate antibiotic 
resistance make it a formidable opportunistic pathogen. Its ability to 
form biofilms, to degrade the lung tissue, to modulate the immune 
defence, and to outcompete other bacteria are key to its persistence and 
chronicity in lung infections. This leads to a fitter pathogen through 
evolution and adaptation. In the next section, the regulatory mechanisms 
of P. aeruginosa are explained. 
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2. Regulation in Pseudomonas aeruginosa 
P. aeruginosa has one of the highest percentages of genes predicted to 
be involved in regulation among sequenced bacteria [4], [116] and the 
regulation occurs on transcriptional, translational and protein levels. 
Furthermore, many genes are regulated by multiple regulators resulting 
in an interwoven mesh of regulation. The major regulators are σ-factors 
(and anti-σ-factors), two component systems (TCSs), and small RNAs 
(sRNAs). The versatility of P. aeruginosa is highly dependent on it 
being able to respond properly to environmental cues and adapt to the 
given circumstances, by expressing the appropriate sets of metabolic 
genes and virulence factors. Regulation in P. aeruginosa is complex and 
many regulatory networks feed into each other as exemplified in Figure 
5. 
 
 
Figure 5. The interconnected regulatory network of virulence in P. 
aeruginosa containing σ-factors, TCSs, and sRNAs. Adapted from 
Balasubramanian, et al., 2012 [117]. 
21 
 
 
2.1. σ-factors 
P. aeruginosa has, as a bacterium, comparatively many σ-factors 
encoded in its genome with 24 putative σ-factors identified so far [118]. 
The σ-factors are responsible for the transcription of groups of genes that 
are necessary under certain circumstances, such as exponential growth 
(RpoD) or the stationary state (RpoS). 
σ-factors function by regulating the transcription of genes by 
recognising their cognate promoters. The σ-factor binds to the RNA 
polymerase core enzyme (α2ββ´ω) forming the holoenzyme (α2ββ´ωσ). 
In this form, the σ-factor can recognise its cognate promoter sequence 
and bind to it. This facilitates the melting of the double-stranded DNA, 
enabling the initiation of transcription by forming the transcription 
bubble. This results in elongation of the transcript from the template 
strand leading to the finished messenger RNA that can then be translated 
into protein or processed further [119]. Defining regulons of σ-factors, 
i.e. what is regulated by the σ-factor, can be difficult since the effects are 
often widespread and feed into a host of other regulatory networks. 
RpoD (σ70), also called the house-keeping σ-factor, is responsible for 
the transcription of genes during exponential growth. It has proven 
difficult to study since it is essential, but a study found that the regulon 
contains at least 686 genes [120] in the P. aeruginosa reference strain 
PA14.  
RpoS (σ38) is generally known as the stationary/stress σ-factor, which 
comes into play during early-stationary phase, when nutrients are 
limited. It has a sizeable regulon of upwards of 800 genes and is heavily 
involved in quorum-sensing, which expands its indirect regulon. It 
activates the expression of genes involved in chemotaxis and TCSs and 
represses genes of central intermediary metabolism, chaperones, and 
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secreted factors. The chemotaxis genes are, in this case, linked to biofilm 
formation rather than motility [121]. Furthermore, the expression of 
RpoS is important for tolerance against antibiotics during stationary 
phase [122].  
RpoN was originally named after its connection with nitrogen 
metabolism. However, it has since been discovered that it has a more 
versatile role. The regulon is about 600 genes in P. aeruginosa PA14 
[120]. It is the only σ-factor that does not show homology to RpoD and it 
functions in a unique way as it requires activator proteins to assert its 
function. Activator proteins either bind to an upstream enhancer 
sequence, which then loops back and binds to the RpoN-RNA 
polymerase holoenzyme, or bind directly to the RpoN-RNA polymerase 
holoenzyme, enabling transcription [123]. 
As noted above, there are many more σ-factors in P. aeruginosa and a 
non-exhaustive list has been provided in Table 2. 
 
Table 2. Non-exhaustive list of σ-factors in P. aeruginosa. Adapted 
from Potvin, et al., 2008 [118]. 
σ-factor Function References 
RpoD House-keeping [120] 
RpoS Stationary/stress 
phase 
[120], [121], [124], 
[125] 
RpoN Versatile [120], [126]–[130] 
RpoH Heatshock response [120] 
RpoF Flagellin synthesis [120], [131] 
RpoE Alginate synthesis [120], [132] 
PvdS Pyoverdine 
synthesis 
[56], [120] 
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2.2. Two-component systems and GacSA 
TCSs are the primary way bacteria sense the environment. P. 
aeruginosa has particularly many of these helping it to adapt to different 
environments. TCSs are composed of a histidine kinase, which detects 
environmental signals, and a response regulator that is phosphorylated by 
the cognate histidine kinase upon activation and thus activates or 
represses expression of genes necessary for the appropriate response. 
The genome of P. aeruginosa PAO1 encodes 64 putative response 
regulators and 63 putative histidine kinases [133]. This large number of 
TCSs allows P. aeruginosa to efficiently sense the environment and 
react accordingly. 
An interesting TCS from an infection point-of-view is the GacSA TCS, 
since it reciprocally regulates gene-expression contributing to either a 
chronic or an acute infection state. The dogma of this regulatory system 
is that chronic genes are defined as the pel/psl biofilm formation operons 
and the H1-T6SS, whereas the acute infection genes are the T3SS, 
flagellum and Type IV pili. The GacSA TCS regulatory system is the 
focus of this thesis because of the occurrence of sequential mutations in 
clinical isolates of P. aeruginosa cultured from patients with CF [134]. 
The system features at least three other histidine kinases that regulate 
the system upstream of GacSA in the regulatory chain. The function of 
GacS, in its dimeric and autophosphorylated state, is to phosphorylate 
GacA, the response regulator, which then becomes active. In its active 
state, GacA activates the transcription of two sRNAs, RsmZ and RsmY, 
the only targets of GacA. These bind to and sequester RsmA, an RNA-
binding protein, through characteristic GGA motifs, preventing it from 
binding to its target mRNAs, relieving suppression of translation and 
increasing mRNA turnover. The regulators of the GacSA-TCS are LadS, 
RetS, and PA1611. RetS is a hybrid histidine kinase that binds to GacS, 
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forming a heterodimer, and prevents the autophosphorylation of GacS. 
LadS, also a hybrid histidine kinase, has the opposite function. It 
functions as a phosphorelay mechanism that donates and relays a 
phosphoryl group to GacS, activating the TCS. Expanding on this is 
PA1611, another hybrid histidine kinase. Its function is similar to GacS 
and interacts with RetS, thus preventing RetS from inhibiting GacS 
(Figure 6). Common for all the histidine kinases in this multicomponent 
system is that the signals leading to their activation are unknown [134]–
[139]. Additionally, this system seems to be a hotspot for mutations in 
CF airway infections with P. aeruginosa [106], [108], [140]. This could 
indicate that the activating signals are not present in the CF airways or 
that mutations are a more efficient way of activating/deactivating the 
signalling cascade. Futhermore, the mutations suggest that this system is 
important for the adaptation of P. aeruginosa to the CF airways. 
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Figure 6. The GacSA TCS and the three histidine kinases (LadS, RetS, 
PA1611) that modulate the system. Activation of GacS leads to 
phosphorylation of GacA, which in turn activates transcription of the 
two sRNAs, RsmZ and RsmY. This leads to expression of chronic 
lifestyle genes. Adapted from Chambonnier, et al., 2016 [135]. 
 
2.3. sRNAs 
Small RNAs (sRNAs) add another layer of regulation to bacteria. As 
the name suggests, they are small RNAs (50-500 bp) that (usually) do 
not code for a protein. Instead, they act by binding to mRNA or proteins 
and modulating their function. Two major classes of sRNAs have been 
defined, cis-encoded sRNAs and trans-encoded sRNAs. Cis-encoded 
sRNAs are encoded antisense to their targets and thus share extensive 
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complementarity with their corresponding transcript. Trans-encoded 
sRNAs are not encoded antisense to their targets and have limited 
complementarity with their targets. These trans-encoded sRNAs often 
require a RNA-chaperone, such as Hfq, to help with base-pairing and 
asserting their function and can have many different targets, which 
expands their regulatory function. As noted above in the GacSA TCS, 
some sRNAs have a different mode of action, where they bind to a 
protein and sequester it, preventing the binding of mRNAs to the protein 
[141]–[144]. However, most sRNAs function by either increasing or 
decreasing translation by binding to mRNAs (Figure 7). 
 
Figure 7. Regulatory mechanisms of sRNAs. A) Target gene repression 
through (I) inhibition of translation initiation, (II) sequestration of a 
ribosome standby site, or (III) stimulation of ribonuclease activity 
increasing mRNA decay. B) Target gene activation through (I) 
releasing a sequestered ribosome binding site by binding elsewhere on 
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the mRNA, or (II) sequestration of ribonuclease cleavage sites to 
decrease mRNA decay thus increasing translation. Adapted from 
Fröhlich, et al., 2016, [145]. 
 
The advent of RNA sequencing (RNA-seq) has facilitated the 
discovery of sRNAs, and more than 500 sRNAs have been identified in 
P. aeruginosa PAO1 [146], Additionally, 223 intergenic sRNAs were 
reported in P. aeruginosa PA14 [147], and another comparative study 
identified a 126 sRNA-overlap between PAO1 and PA14 [148]. This 
suggests that they are integral to regulation, but also that they are 
involved in strain specific regulation that could have important 
consequences for the virulence of a specific strain. However, few of 
them have been characterised. The ones that have been characterised 
have been shown to have diverse functions and some are involved in the 
expression of virulence factors. A few examples follow here. 
PrrF1 and PrrF2 are two sRNAs involved in iron homeostasis in P. 
aeruginosa. They are >95% identical and are induced under iron 
limitation. They are encoded in tandem and seem to function in a 
redundant manner. Curiously, another transcript and sRNA, PrrH, spans 
both of these. Deletion of the PrrF-locus encoding the sRNAs, leads to 
loss of virulence in a murine model of acute lung infection [149]–[151]. 
PhrS is a sRNA that is expressed by ANR, the anaerobic 
transcriptional regulator, when oxygen is limited. It increases the 
translation of PqsR, through a structural rearrangement of the mRNA 
containing the open reading frame of PqsR, which leaves the ribosomal 
binding site open for binding by the ribosome. PqsR is a positive 
regulator of the Pseudomonas quinolone signal operon, an intercellular 
signal molecule, and the phenazine biosynthesis operons [152]. 
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CrcZ is a small RNA, functioning much like RsmZ and RsmY.  
However, it requires the RNA-chaperone, Hfq, to exert its function. The 
target of CrcZ is the Hfq-Crc complex, which is involved in carbon 
catabolite repression. The Hfq-Crc complex exerts its regulatory function 
by binding to mRNA transcripts and preventing their translation. CrcZ 
thus relieves the post-transcriptional regulation of the Hfq-Crc complex 
[153]. CrcZ expression is regulated by a TCS, CbrAB, where CbrA is the 
histidine kinase and CbrB is the response regulator. CbrB is predicted to 
have a RpoN-binding domain and thus functions as an activator protein 
[12], [153]–[155]. The carbon catabolite repression mechanism is a clear 
example of the complexity of regulatory networks and how they feed 
into each other and cause a cascade of regulatory changes. 
 
In this section, the regulatory systems of P. aeruginosa were explained 
with special focus on the GacSA TCS. It is apparent that regulation in P. 
aeruginosa is a complex matter and that mutations in multiple regulators 
can lead to results that are not immediately apparent from the single 
mutations. In the next section, the sequence of events leading to the 
conception of this PhD-thesis is described. 
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3. Rationale of the present study 
The advent of NGS has enabled massive genome sequencing of 
clinical isolates of P. aeruginosa and the dawn of a new era in the 
elucidation of how bacteria evolve during long-term infections [105], 
[106], [156]. This could lead to the development of new treatment 
strategies and personalised medicine. However, most studies on the 
evolution of P. aeruginosa focus on genomics and phenotypes, and few 
studies examine the transcriptomic evolution of longitudinal isolates.  
A study by Yang, et al., 2011 [157] used genome sequencing, 
microarray transcriptomic profiling (Affymetrix), and Biolog phenotypic 
profiling to assess the evolution of longitudinal isolates of the dominant 
Copenhagen clone types, the DK2 lineage, collected over a period of 40 
years. In total, 12 clinical isolates from six patients were examined. They 
showed that the early and late stages of evolution have different 
characteristics. The initial stage of evolution was shown to be based on 
positive selection as measured by the ratio of non-synonymous mutation 
to synonymous mutations (dN/dS) being more than 1. This tells us that 
the majority of mutations likely result in altered function of proteins 
during the first six years of evolution improving the fitness of P. 
aeruginosa in its new environment. However, later in the infection the 
pattern is the opposite and instead the dN/dS ratio drops below 1, 
suggesting after the initial stages of infection, adaptation slows down 
since mutations can no longer improve fitness to the same extent. This 
was supported by the use of transcriptomic and phenotypic profiling. The 
majority of changes in the transcriptome and metabolism occurred in the 
first six years, again suggesting that the initial period is where the major 
adaptation occurs. Furthermore, they found that mutations in mucA (anti-
sigma factor of AlgU, alginate biosynthesis), lasR (quorum-sensing 
transcriptional regulator), and rpoN accounted for half the differential 
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gene expression in the first six years, showing the role of mutations in 
regulatory genes in rapid adaptation. 
Closer inspections of mutations in DK2 isolates revealed elaborate 
rewiring of regulatory networks by Damkiær, et al., 2013 [158]. Here, 
the wild-type alleles were replaced with the evolved alleles of mucADK2 
(frame-shift), algTDK2 (substitution), rpoNDK2 (substitution), lasRDK2 
(deletion), and rpoD DK2 (in-frame deletion) in P. aeruginosa PAO1 in a 
sequential manner and the effects examined. Through a combination of 
phenotypic assays and gene-expression profiling (microarray), it was 
discovered that the combination of mutations produced effects that are 
not obvious from the individual mutations (i.e. epistasis). Four mutations 
(not including rpoDDK2) accounted for 40% of the differential gene 
expression comparing the clinical isolate and the PAO1 with allelic 
replacements to PAO1. Hereafter, mutants of PAO1 (mucADK2+algT DK2, 
rpoNDK2, and lasRDK2) were constructed and compared their expression 
patterns to PAO1 and the PAO1 Q-mutant, containing mucADK2+algT 
DK2, rpoNDK2, and lasRDK2, showing that while the mutations in some 
cases act directly or additively on the differential expression of genes, 
there were also many genes that were only upregulated through the 
epistasis of all four mutations. Indeed, the combination of all four 
mutations in the PAO1 Q-mutant led to a significantly increased 
resistance to ceftazidime and tobramycin, while other combinations of 
mutations did not. This demonstrates that mutations in regulatory 
networks can interact in non-obvious manners and result in effects that 
are only apparent when the mutations can interact with each other. It also 
serves as a warning of a gene-centric view of evolution and shows that 
the sum of mutations is greater than the parts. However, the DK2 lineage 
seems to be a special case as it was highly transmissible and evolved in a 
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different manner than what is observed in younger patients as described 
below. 
These studies prompted the investigation of clinical P. aeruginosa 
isolates from early CF airway infections as the majority of changes 
happen in the early stages, leading to the study of Marvig, et al., 2015 
[106]. Here, 474 clinical P. aeruginosa isolates from early CF airway 
infections in 34 patients were whole genome sequenced in order to 
elucidate the evolutionary trajectories and determine if they follow the 
same pattern, i.e. convergent evolution. 36 lineages of P. aeruginosa 
were discovered as defined by >10,000 single nucleotide polymorphisms 
between lineages. The study shows that there are 52 genes that are hit 
more often by mutations than would be expected by chance, called 
pathoadaptive mutations. Ten of these are predicted to be transcriptional 
regulators. Another discovery was that mutation in the retS-gacS-gacA-
rsmA-rsmYZ signaling pathway and the mucA/algU system occur only in 
a specific order. Mutations would always appear in retS before the 
downstream genes of gacS, gacA, and rsmA. The first mutation in retS 
leads to a chronic infection mode, whereas the second mutation leads to 
an acute infection mode. In the case of mucA/algU, there were no cases 
of algU mutating before mucA. 
The work in this thesis stems from the 474 clinical isolates. The 
discovery that mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling 
pathway occur only in a specific order was interesting as it is a system 
determining the expression of specific virulence factors. We decided to 
look into the effects of these mutations in two lineages. First by 
examining the evolutionary trajectories of seven clinical isolates with all 
the residual evolution included, i.e. mutations in other genes. Secondly, 
by examining the specific effects of the mutation by replacing the alleles 
in the non-evolved strains with the mutations in retS and gacS of the 
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evolved strains. Furthermore, we also replaced the mutated versions of 
retS and gacS in the evolved-strains with the functioning versions from 
the non-evolved strains, which would show the effects of all the 
mutations that are not in the retS-gacS-gacA-rsmA-rsmYZ signaling 
pathway. The current dogma of this system is that it reciprocally 
regulates chronic and acute infection [134]–[139] modes, but this may 
not be an accurate nomenclature, as the sequential nature of the 
mutations are the reverse of what would be expected if this were true.   
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4. Concluding remarks and perspectives 
In this thesis, we show that the initial stages of evolution and 
adaptation of two lineages of P. aeruginosa to the CF airways are 
complex and characterised by the differential and temporal expression of 
a multitude of virulence factors. This suggests that the evolution of the 
initial stages of infection is the result of a changing environment, where 
the expression of virulence factors is tailored to what is needed at a 
certain point of time due to external circumstances, such as competing 
microbes, the host defence, and available nutrients. 
In the first paper (in preparation), we investigate two lineages of P. 
aeruginosa isolates from two patients with CF, harbouring their own 
lineage. Using transcriptomics and proteomics, we investigate how the 
transcriptome and proteome change over a period of four years of 
adaptation to the CF airways. The lineages have sequential mutations in 
the retS-gacS-gacA-rsmA-rsmYZ signaling pathway, which shifts the 
expression of virulence factors. We show that the mutations in the retS-
gacS-gacA-rsmA-rsmYZ signaling pathway are a major source of 
variation in both the transcriptome and proteome. This leads to 
differential expression of virulence factors in a reciprocal manner. 
Additionally, we show that we can correlate mutations in other 
regulators to their respective transcripts and proteins in complex 
mutational settings. The reciprocal expression of virulence factors 
suggests that the selective pressure of the CF airways changes over time 
and that the expression of virulence factors is tailored to this. The 
significance of from where the strains were isolated from still needs to be 
examined, as the DK17 strains were primarily isolated from the sinuses 
and the DK41 strains were isolated from the lower airways, which could 
have a role in the evolutionary trajectories. 
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In the second paper (in preparation), we examine the same strains, but 
replace the mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling 
pathway with their wildtype versions. This leads to the discovery that the 
residual mutations not occurring in this signalling pathway also influence 
the expression of the virulence factors. This shows that inferring a 
specific evolutionary trajectory in complex mutational settings does not 
show the full picture of evolution. Some mutations will hide the effects 
of other mutations on a transcriptome level, underlining the complex 
regulatory network of P. aeruginosa. This paper still needs a significant 
amount of work, in particular in examining how similar mutations in two 
genetic backgrounds behave differently, and a deeper analysis of the 
proposed differential expression of rpoD and rpoS is needed. 
These results challenge the idea of the retS-gacS-gacA-rsmA-rsmYZ 
being a regulator of chronic and acute infection modes in P. aeruginosa. 
Indeed, if the nomenclature of this system was apt, it would be expected 
that mutations in retS would be predominant in P. aeruginosa in the CF 
airways. However, the effects of the retS-mutations are reversed by a 
later mutation in either gacS or gacA that should lead to an acute 
infection mode, the reverse of the dogma in infections of the CF airways. 
Instead, it seems that the initial retS-mutation facilitates the 
establishment of the infection, whereas the sequential gacS/gacA 
mutations could be a response to environmental changes, due to airway 
remodeling, host response, or changes in the microbiome.  
The work in this thesis expands the knowledge on the early stages of P. 
aeruginosa evolution and adaptation in CF infections and shows that a 
gene-centric view on a genomic level is not enough to accurately 
describe the evolutionary trajectories, showing the need for more 
research on the early evolution and adaptation of P. aeruginosa in CF 
airways on a transcriptomic level to properly understand the mechanisms 
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of adaptation. Additionally, there is an urgent need for model systems 
that possess the selective pressures found in the CF airways. The 
behaviour of P. aeruginosa in the CF airways needs to be accurately 
determined for example by in vivo transcriptomics. This could give some 
hints to what the bacteria are experiencing, enabling the simulation of the 
infection setting. This should be compared with the available model 
systems to determine how well these systems model the CF airways. 
Furthermore, the knowledge gained from this would facilitate the 
development of new model systems that would enable a more exact 
replication of the stressful environment of the CF airways. It is highly 
likely that we are missing key aspects of the behavioural mechanisms 
due to the inadequacy of modelling the CF airways.  
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Summary 9 
Pseudomonas aeruginosa causes long-term infection in the airways of patients with 10 
cystic fibrosis (CF) leading to significant morbidity and mortality. During this time, 11 
mutations will occur in P. aeruginosa as it adapts and evolves to the environment of 12 
the CF airways. The evolution is characterized by loss of virulence factors, increased 13 
antibiotic resistance and increased biofilm formation or mucoidy. Here, the 14 
evolutionary trajectories of two lineages (DK17 and DK41) of P. aeruginosa isolated 15 
from two young CF patients are investigated at the transcriptomic and proteomic 16 
levels. Seven strains were isolated over a period of approximately four years and both 17 
lineages have sequential mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling 18 
pathway, a key regulatory system for the expression of virulence factors. The data 19 
show that the mutations in this system are the major cause of variation in the 20 
transcriptomes and proteomes, but that the lineages are also a significant source of 21 
variation. Furthermore, the mutations lead to reciprocal expression of the type III and 22 
the type VI secretion systems, suggesting that P. aeruginosa needs to express 23 
different virulence factors at different times during the early stages of infection in 24 
response to selection pressures. Additionally, one lineage seems to adapt to microoxic 25 
conditions as there is an increased expression of denitrification genes with respect to 26 
time of isolation of the isolate. Both lineages also acquire mutations in regulators of 27 
resistance-nodulation-division (RND) efflux-pumps, which leads to increased 28 
expression of multiple efflux pumps. Furthermore, in line with the similar mutations 29 
in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway the transcriptomes and 30 
proteomes converge through time, suggesting that the lineages are on similar 31 
evolutionary trajectories. 32 
Introduction 33 
Pseudomonas aeruginosa is a major pathogen of cystic fibrosis (CF) infections and 34 
leads to significant morbidity and mortality in patients. The majority of cystic fibrosis 35 
patients will acquire a P. aeruginosa infection at some point in life [1]. These 36 
infections may persist for decades giving the bacteria ample time to adapt and evolve 37 
to their new niche by accumulation of mutations. Especially the first years of 38 
infection are important for the adaptation, when large scale phenotypic changes occur 39 
[2]. In line with this, mutations will often occur in regulatory genes and perturb 40 
regulatory networks, which can lead to massive phenotypic changes facilitating quick 41 
adaptation to the CF airways [3]. The usual evolutionary trajectories concern the loss 42 
of virulence factors, increased antibiotic resistance, and increased biofilm formation 43 
or mucoidy caused by overproduction of alginate [2], [4], [5]. However, little is 44 
known about the selective pressures and the reasons why P. aeruginosa evolves in the 45 
way it does. Upon entering the body, the bacteria meet the host immune system and a 46 
new environment with new energy and carbon sources available. Furthermore, in the 47 
attempt to get rid of or curb the infection, patients are treated with numerous 48 
antibiotics, which also represent a strong selective pressure for P. aeruginosa [6]. 49 
The retS-gacS-gacA-rsmA-rsmYZ signaling pathway plays a key regulatory role in the 50 
reciprocal switching between acute and chronic infection modes. The pathway works 51 
through RetS, a hybrid sensor kinase, which inhibits autophosphorylation of GacS, a 52 
histidine kinase. GacS, in its active phosphorylated and dimeric state, activates GacA, 53 
the cognate response regulator of GacS, which activates transcription of two small 54 
RNAs, RsmZ and RsmY. These RNAs sequester RsmA and prevent it from binding 55 
to its target mRNAs, thereby relieving the repression of translation [7], [8]. However, 56 
RsmA is also capable of promoting the expression of genes [9]. Under acute infection 57 
conditions, where RsmA is not sequestered by RsmZ and RsmY, there is expression 58 
of the type III secretion system (T3SS), type IV pili, type II secretion, toxA, and lipA 59 
[10]. However, chronic infection conditions (where RsmA is sequestered) are 60 
characterized by expression of the pel and psl operons promoting biofilm formation 61 
and the type VI secretion system (T6SS). The RsmA-regulon contains upwards of 500 62 
genes with regulation occurring in both ways either directly at the level of translation 63 
or indirectly through regulation of regulatory factors [11].  64 
Here, we investigate the evolution of two lineages of P. aeruginosa from two young 65 
CF patients comprising a total of seven clinical isolates. Using both transcriptomic 66 
and proteomic approaches, we attempt to elucidate the evolutionary trajectories of 67 
these lineages that harbor not only sequential mutations in the retS-gacS-gacA-rsmA-68 
rsmYZ signaling pathway, but are also mutated in other genes.  69 
Results 70 
Sequential mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling 71 
pathway 72 
In a previous study [5], 11 cases of nonsynonymous mutations in the retS-gacS-gacA-73 
rsmA-rsmYZ signaling pathway were recorded. The mutations appeared in a 74 
sequential manner, where retS always mutated before gacS, gacA, or rsmA, strongly 75 
suggesting selection for this sequential mutational pattern (Figure 1).  76 
 77 
Figure 1. A timeline of the sequence of isolation of strains from the patients. The 78 
black symbols represent the isolates used in this study, whereas the light grey were 79 
also isolated from the patients, but not used in the study. The mutations in the retS-80 
gacS-gacA-rsmA-rsmYZ signaling pathway are symbolized by the symbol. The 81 
symbols have been scattered along the y-axis for clarity as samples were taken at the 82 
same time.  83 
 84 
The strains were isolated from two patients (female, born in 1996/male, born in 2001) 85 
over approximately a four-year period and belong to two different lineages of P. 86 
aeruginosa, DK17 and DK41, with each patient being colonized exclusively with one 87 
lineage (Table S1). The mutations in gacS, gacA, and retS all occur in the first half of 88 
the genes and are either indels causing frameshifts or, in one case, a SNP causing a 89 
stop codon, suggesting that in every case all gene function is abolished (Figure 2). 90 
However, other mutations also occur (Table S2). The first isolate of either lineage will 91 
be referred to as the most recent common ancestor (MRCA). 92 
 93 
Figure 2. A map showing the proteins with domains, as predicted by pfam [41], of 94 
RetS, GacS, and GacA. The location and type of the mutations in the retS, gacS, and 95 
gacA genes are shown for both clone types. 7TM = seven-transmembrane domain, 96 
His Kinase A/HisKA = histidine kinase phospho-acceptor domain, GHKL = histidine 97 
kinase-, DNA gyrase B-, and HSP90-like ATPase domain, Receiver = response 98 
regulator receiver domain, His Kinase = uncharacterized signal transduction histidine 99 
kinase domain, HAMP = histidine kinase, adenyl cyclase, methyl-accepting proteins, 100 
and phosphatase linker domain, HPt domain = histidine-containing phosphotransfer 101 
domain, HTH =  LuxR-type DNA-binding helix-turn-helix domain. 102 
Proteomics and RNA-seq 103 
The samples taken for proteomic and transcriptomic analysis were harvested from the 104 
same cultures at the same time grown at 37 °C in LB medium in late exponential 105 
phase. The protein extraction protocol favored cytosolic proteins, which were 106 
quantified through LC/IMSE and mapped to P. aeruginosa PAO1. In total, 1351 107 
proteins were identified in the DK17 lineage and 1273 in DK41 lineage. The majority 108 
of the proteins are predicted to be cytosolic proteins and are thus overrepresented in 109 
the data compared to the database used, as expected (Table 1). The overlap between 110 
the two proteomes of the lineages was 1166 proteins. Tables showing all proteins 111 
quantified are given as supplemental tables (Tables S4A and S4B). RNA was 112 
harvested and converted into cDNA and sequenced on MiSeq and mapped to the 113 
genome of P. aeruginosa PAO1 with an average of 3.53 million mapped reads (Table 114 
S3). 115 
 116 
Table 1. Number of detected proteins of the DK17 and DK41 lineages and their 117 
localization as predicted by PSORTb [43]–[45]. 118 
Localization DK17 DK41 Database (PAO1) 
Cytoplasmic 964 (71.3%) 903 (70.9%) 2591 (46.6%) 
Cytoplasmic membrane 88 (6.5%) 89 (7.0%) 1273 (22.9%) 
Periplasmic 59 (4.4%) 53 (4.2%) 170 (3.1%) 
Outer membrane 24 (1.8%) 27 (2.1%) 172 (3.1%) 
Extracellular 13 (1.0%) 14 (1.1%) 69 (1.2%) 
Unknown 203 (15.0%) 187 (14.7%) 1285 (23.1%) 
Total 1351 (100.0%) 1273 (100%) 5560 (100%) 
 119 
Regulatory mutations are a major source of variation 120 
With the aim of determining the evolutionary trajectories of two lineages of P. 121 
aeruginosa from early cystic fibrosis airway infection, and in order to investigate the 122 
major sources of variation in the transcriptomes and proteomes, principal component 123 
analysis (PCA) was used. The PCA biplot shows the two major factors/components 124 
causing variability and interestingly for the transcriptomic data (Figure 3), the first 125 
component is represented by mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling 126 
pathway, where a negative value corresponds to a mutation in retS and a positive 127 
value corresponds to a mutation in both retS and gacS/gacA.  128 
 129 
Figure 3. A PCA-biplot of the transcriptome data showing only the virulence factors 130 
as obtained from [42]. Component 1 describes 34.3 % of the total variation whereas 131 
component 2 describes 29.9 %. Colors describe the virulence factor class. The 132 
loadings of the PCA are shown in black and have been amplified for clarity and are 133 
thus not to scale. 134 
 135 
This indicates that the majority of the transcriptomic changes is indeed caused by 136 
mutations in retS/gacS/gacA and confirms the reciprocal nature of the regulation. 137 
Additionally, the second component (29.9%) divided the clone types with a positive 138 
value representing DK17 and a negative value representing DK41 showing that the 139 
lineage or genetic background of a strain has a large influence on the transcriptome. 140 
Figure 3 clearly shows that the expression of certain virulence factors is associated 141 
with mutations in retS/gacS/gacA. Indeed, the TT6S, phenazine biosynthesis genes 142 
(phz1/phz2), the hydrogen cyanide biosynthesis cluster (hcnABC), rhamnolipid 143 
biosynthesis (rhlAB), protease (lasA), and elastase (lasB) are all associated with 144 
mutations in retS. Conversely, mutations in gacS/gacA are associated with higher 145 
expression of the T3SS and lower expression of the aforementioned. Component 3 146 
(11.5%) (data not shown) shows no major trends for DK17. However, for DK41 the 147 
strains are distributed along the component with respect to the time of when the 148 
strains were isolated. Interestingly, the later strains are associated with expression of 149 
nir/nor/nos genes that are all part of the denitrification pathway.  150 
A similar tendency is seen in the proteomics dataset (Figure S1). Here, the first 151 
component (39.1%) seems to describe the lineage specific differences and the second 152 
component (33.4%) describes the mutations in retS/gacS/gacA. The picture is not as 153 
clear as for the transcriptomes. The difference is likely due to the proteomes 154 
representing a subset of all proteins, whereas the transcriptomes describes the full 155 
mRNA population. The third component is, however, not linked to any denitrification 156 
genes. A likely explanation is that only one of the denitrification genes is identified in 157 
the dataset (nosZ). 158 
Secretion systems and antibiotic resistance genes are differentially 159 
expressed 160 
To determine what PseudoCAP groups of genes and proteins that were differentially 161 
expressed/abundant in all strains across the lineages, we used ANOVA (p < 0.05) on 162 
both the transcriptomics and proteomic datasets with respect to lineages and found 163 
that in DK17 680 genes were differentially expressed in the transcriptome and 543 164 
proteins were differentially abundant in the proteome with an overlap of 176 genes. In 165 
DK41, 146 genes were differentially expressed in the transcriptome and 319 in the 166 
proteome with an overlap of only 36 genes. The large difference in differentially 167 
expressed genes between lineages can be partially explained by DK17 having four 168 
strains and DK41 having three strains. 169 
By comparing the number of differentially expressed genes in a PseudoCAP function 170 
class [12] with the total number of genes in the genome of a PseudoCAP function 171 
class compared to the overall number of genes in the entire genome, we can by using 172 
a binomial distribution determine whether some function classes are overrepresented 173 
in the total number of differentially expressed genes. Doing this for both lineages, we 174 
see that both the transcriptomic and proteomic datasets agree that some groups are 175 
overrepresented (Figure 4).  176 
 177 
 178 
Figure 4A + B. Differential expression of PseudoCAP groups for transcriptome and 179 
proteome. The ratios show whether genes are more or less differentially expressed 180 
than would be expected if all genes had equal chance of being differentially 181 
expressed. A ratio of more than one means that this group is more differentially 182 
expressed than would be expected if differential expression were completely random. 183 
 184 
In line with the results from the principal component analysis, the groups called 185 
“Protein secretion/export apparatus”, “Secreted factors”, and “Antibiotic resistance 186 
and susceptibility” are overrepresented among differentially expressed genes for both 187 
lineages. The first group contains 142 genes that are part of the type I secretion 188 
system, type II secretion system, T3SS, and T6SS. Of these, 52 in DK17 and 21 in 189 
DK41 are differentially expressed in the transcriptomes. For both lineages, the genes 190 
are primarily parts of the Type 3 and Type 6 secretion systems. In DK17 and DK41, 191 
the T6SS system shows higher expression (2-fold and 4-fold, respectively) in the 192 
isolates with the retS-mutation and lower expression (8-fold and 64-fold, respectively) 193 
in the isolates that also contain either the gacS or gacA mutation compared to the retS-194 
mutants. For the T3SS, there is virtually no expression in the retS mutants of either 195 
lineage. However, in the gacS mutants, the expression is increased 8-fold and 16-fold 196 
in the gacA mutant as compared to their respective MRCA. In line with the reciprocal 197 
nature of the retS-gacS-gacA-rsmA-rsmYZ signaling pathway the T3SS is expressed 198 
in the opposite manner of the T6SS, meaning that it is downregulated in the retS-199 
mutant and upregulated in the gacS/gacA mutants. In the proteomics data, expression 200 
of the T6SS was only observed in the retS mutants with the exception of few proteins 201 
being quantified in the MRCAs, likely due to their membrane-associated nature. 202 
Interestingly, the mutation in gacA, the response regulator, has a larger effect on 203 
expression than the gacS-mutation, which can also be seen in Figure 3 as the loading 204 
for the retS-gacA mutant is placed further on the first component than the retS-gacS 205 
mutant. This can be explained by the fact that a mutation in a response regulator could 206 
completely abolish the function of it, whereas some residual function may still be 207 
present even if its cognate histidine kinase is not functional or perhaps through 208 
crosstalk with other histidine kinases. 209 
The “Secreted factors” group contains 97 genes encoding the products that are 210 
secreted and the enzymes necessary for the production of secreted compounds. These 211 
include effector proteins of the T3SS and T6SS, but also phenazine biosynthesis 212 
genes. The phz1 and phz2 operons are 4-fold upregulated in the DK17 retS mutant 213 
compared to the first isolate. Interestingly, a similar pattern is not observed between 214 
the DK41 retS mutant and the DK41 MRCA. However, for both DK17 and DK41, the 215 
retS and gacS isolates, show 32- and 8-fold decreases in expression for the phz1 and 216 
phz2 operons, respectively, compared to the retS isolates. The retS, gacA isolate of 217 
DK17 shows virtually no expression of either the phz1 or phz2 operons. The phz1 and 218 
phz2 operons were only detected in the retS mutants in the proteomic data in line with 219 
these isolates showing the highest mRNA expression in the same isolates. 220 
Lineage specific trends 221 
Some genes are either only expressed or show a much higher expression in one 222 
lineage. Examples include pilA, exoS, exoY, and pchR that are only expressed in 223 
DK41 and pldA in DK17 as seen in Figure 3. This is caused by the differences in 224 
genetic content as the aforementioned genes are not present in DK17.  225 
As noted above, the expression of denitrification genes is higher in later isolates of 226 
DK41 while DK17 has a more erratic pattern. In DK17, the retS mutant and the retS-227 
gacA mutant show low expression while the MRCA and the retS-gacS show a high 228 
expression. Moreover, not all genes in the denitrification pathway show higher 229 
expression over time. The genes responsible for the first conversion step of nitrate to 230 
nitrate are not upregulated, but the remaining steps containing the conversion of 231 
nitrite → nitric oxide → nitrous oxide → N2 (nir/nor/nos) [13] are, suggesting a very 232 
specific evolutionary pressure. Only one protein in the denitrification pathway was 233 
identified in the proteome data, namely NosZ, which is responsible for the conversion 234 
of nitrous oxide into molecular nitrogen. It was only detected in isolates R, M, and 235 
364, which correlates with high mRNA expression. The first isolate in DK17 shows a 236 
higher expression of the previously mentioned denitrification genes than the first 237 
isolate of DK41. Indeed, it is not until the last isolate of DK41 (~4 years from first 238 
isolate) that DK41 has similar expression levels of denitrification genes as the first 239 
isolate of DK17. This can explain why differential expression of the denitrification 240 
pathway genes is not seen in DK17. Simply put, the level of expression was already 241 
high enough from the outset.  242 
Furthermore, in both lineages there are trends of increasing expression concerning 243 
multidrug efflux systems of the resistance-nodulation-division family. In DK17, the 244 
mRNA levels of mexXY[14] and mexCD-oprJ[15] increase with the later isolates, 245 
where the retS, and retS, gacS, and retS, gacA isolates have up to 16-fold higher 246 
expression than the MRCA.  None of the respective proteins were detected, likely due 247 
to these being membrane-bound proteins that are not favored with the protein 248 
extraction protocol. The expression of the mexXY-genes is controlled by the repressor, 249 
MexZ [16], which incidentally has a missense mutation in the DNA-binding HTH 250 
domain in the later isolates with higher expression of mexXY. This strongly suggests 251 
that this mutation affects the repression abilities of MexZ. In line with this, a 14-bp 252 
deletion in mexR is identified in the retS, gacA-mutant and is not present in isolates 253 
MRCA, retS, and retS, gacS. mexR is a repressor of the mexAB-oprM operon and a 254 
negative autoregulator of itself [17]. In the retS, gacA-mutant, the mRNA levels of 255 
mexAB-oprM are up to 8-fold higher than in the other isolates of DK17, again 256 
suggesting that this mutation affects protein function and leads to faulty repression 257 
(Figure 5).  258 
 259 
Figure 5. Expression of mRNA of the antibiotic resistance operons mexAB-oprM, 260 
mexCD-oprJ, mexEF-oprN, and mexXY. The upper part shows the expression of the 261 
various antibiotic resistance operons, whereas the bottom part shows whether or not a 262 
mutation is present in one of the regulators of the operons. A dot represents a 263 
mutation. 264 
 265 
In DK41, there is also an upregulation of mexR and mexAB-oprM in the two later 266 
isolates (retS and retS, gacS-mutants) as compared to the MRCA. Again, this increase 267 
in expression coincides with a one bp deletion in the beginning of mexR in the later 268 
isolates, likely leading to a non-functional protein. As before, this explains the 269 
increased expression of the mexAB-oprM operon, and shows the negative 270 
autoregulation of mexR. Also the regulator of the mexEF-oprN operon is mutated in 271 
this lineage. Interestingly, the regulator, MexT, is a positive regulator [18], [19], 272 
meaning that the mutation, a one bp deletion, is likely to lower the expression of the 273 
mexEF-oprN operon. Indeed, this seems to be the case (Figure 5). However, MexT 274 
has also been implicated in regulation of the T3SS through MexS and PtrC [20]. The 275 
effects of the mutation in mexT on the expression of the T3SS cannot be determined 276 
since it is not possible to discern the effects in this mutation from the effects of the 277 
mutations the retS-gacS-gacA-rsmA-rsmYZ signaling pathway. 278 
Another interesting trend is the apparent decreased expression of the arn-operon 279 
(arnBCADTEF) again in the later isolates of DK41 (data not shown). This operon is 280 
responsible for a LPS modification system leading to increased resistance towards 281 
cationic antimicrobial peptides, polymyxin B/E, and aminoglycosides by addition of 282 
positively charged arabinosamine to lipid A [21], [22]. This is surprising and 283 
noteworthy as it could lead to a lower resistance against the aforementioned 284 
antibiotics that are used as treatment in cystic fibrosis patients. 285 
The transcriptomes and proteomes converge through time 286 
An interesting aspect concerns evolutionary convergence, where lineages will 287 
converge towards a similar phenotype, simply because it is the fittest for a given 288 
environment. One way to examine whether this is the case for the given strains would 289 
be to correlate the transcriptomes and the proteomes of the lineages to each other.  290 
As shown in Figure 6, the Pearson’s correlations coefficients for both transcriptomes 291 
and proteomes are generally high. The first isolates for both lineages have a 292 
correlation of 0.908 and 0.854 for proteomes and transcriptomes, respectively. 293 
Moving to the retS-mutants, there is a drop in correlation for both datasets 294 
(0.886/0.847) suggesting that in the initial stages of adaptation, the lineages are on 295 
divergent trajectories. However, by the time the gacS mutation is introduced into the 296 
lineages, the proteomes and transcriptomes have converged (0.951/0.884) to the 297 
highest correlation between any two isolates not belonging to the same lineage. This 298 
suggests that there is indeed an evolutionary trajectory towards a common fitness 299 
peak for both lineages.  300 
Another interesting perspective is that, initially, DK17 is more inclined towards the 301 
chronic state of the retS-gacS-gacA-rsmA-rsmYZ signaling pathway. The first isolate 302 
of DK17 is most highly correlated with the retS-mutant of DK41. In line with this, the 303 
expression of the phenazine biosynthesis operons is higher in the first isolate of DK17 304 
than in the first isolate of DK41.  305 
Discussion 306 
The sequential and contingent nature of the mutations in the retS-gacS-gacA-rsmA-307 
rsmYZ signaling pathway, strongly suggests a selection for a specific phenotype 308 
during a specific time point during the course of infection. If this is not the case and 309 
the end-point of evolution (retS-gacA/S double mutation) is the fittest phenotype 310 
during any stage of infection, it would be expected that the gacA/S mutations would 311 
occur more or less as soon as P. aeruginosa enters the airways. This suggests that the 312 
evolution and adaptation of P. aeruginosa is not a trivial process, but instead a 313 
process that changes over time possibly due to changes in the environment such as the 314 
host airways, host response, or other bacteria/fungi. Numerous studies of P. 315 
aeruginosa isolates from CF airway infections have shown selection against acute 316 
virulence factors [3], [5], [23]. However, this study shows a more nuanced picture 317 
where certain virulence factors are expressed during certain periods of infection. 318 
Furthermore, some parts of the retS-gacS-gacA-rsmA-rsmYZ signaling pathway that 319 
have been previously reported to be controlled by RsmA [11], were found not to be 320 
differentially expressed in this study, e.g. the pel and psl operons involved in biofilm 321 
formation. This could suggest that either other mutations have an effect against this 322 
differential expression during infection, or that the regulon can be different from 323 
strain to strain as it was reported in P. aeruginosa PAK using microarrays and under 324 
different conditions [10]. 325 
It is possible to speculate as to why these mutations occur in this manner during 326 
infection. The initial retS mutation, leading to increased expression of the T6SS, 327 
phenazines, HCN biosynthetic genes, and more, could be seen as a defense 328 
mechanism during the early stages of infection, where competing bacteria, the 329 
immune system, and antibiotics cause stress. Here, the most important aspect of 330 
infection for P. aeruginosa is survival and the establishment of a niche. Phenazines 331 
have been shown to have antimicrobial, antifungal [24], and antimammalian [24] 332 
activity by causing oxidative stress. This has obvious advantages during the early 333 
stages of infection, when the immune system will react to the infection. However, the 334 
later gacA/S mutations with downregulation of the aforementioned genes and 335 
upregulation of T3SS suggests that after the initial niche-establishment, there is a 336 
need for dissemination of the infection. Here, the P. aeruginosa spreads from the 337 
initial focus of infection and the response of the immune system response is battled by 338 
the T3SS, which has been suggested to kill host immune cells[25]. 339 
It is surprising that the mutations are necessary to change the phenotype of P. 340 
aeruginosa. As the retS-gacS-gacA-rsmA-rsmYZ signaling pathway is a regulatory 341 
system, it could be expected that it would be able to perform its function without 342 
being rendered inoperable by mutations. However, the signals that this system 343 
responds to are not known [7], [10], [11], and this could suggest that the necessary 344 
signals for the regulation of the system are simply not present in the human airways. 345 
Another possibility is that mutations are more effective at changing the expression of 346 
the necessary genes compared to the signals, and that maximum expression is needed 347 
in the new environment of the airways.  Thus, the only way to regulate the expression 348 
of the controlled genes is to mutate the regulators. 349 
The biggest part of the variance of both the transcriptome and the proteome datasets is 350 
to be explained by the mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling 351 
pathway. A pitfall of this is that both datasets were mapped to the genome of the 352 
reference strains, PAO1. As such, genes that are present in either DK17 or DK41, and 353 
not in PAO1, are not taken into consideration. If these genes are numerous and 354 
different between the two lineages, these would increase the transcriptomic and 355 
proteomic diversity, leading to lineages being the greatest source of variance. 356 
The increased expression of the denitrification genes in the DK41 isolates can be 357 
linked to two things; (i) the cystic fibrosis mucus has been shown to be microoxic 358 
[26], [27] and therefore there is a need for an electron acceptor other than molecular 359 
oxygen, and (ii) the immune system can produce nitric oxide (a reactive nitrogen 360 
species) as a response to the infection, which can disperse biofilms [28], [29] and 361 
damage cells through nitrosative stress [30]. It seems likely that the reason for the 362 
increased expression is a combination of both things. Furthermore, some components 363 
of the denitrification pathway have also been linked to functional expression of the 364 
T3SS [31], showing that metabolism and virulence can be linked. 365 
Interestingly, the correlation coefficients for the transcriptomes and proteomes are the 366 
highest for the last isolates of both lineages with the gacS and retS mutations. This 367 
suggests that the lineages are on a common evolutionary trajectory and concords with 368 
the similar mutations observed in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway. 369 
The fact that both strains seemingly reach an evolutionary dead-end, seeing as it was 370 
not possible to obtain more isolates for years after, suggests that the evolutionary 371 
trajectory of sequential mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling 372 
pathway is not a viable path of adaptation.  373 
Overall this work shows that the early stages of evolution and adaptation to the CF 374 
airways are subject to temporal expression of different virulence factors in P. 375 
aeruginosa. Specific mutations in regulatory systems confer expression of either the 376 
T6SS and the phenazine biosynthesis operons or the T3SS in a sequential manner. 377 
Furthermore, mutations in regulators of antibiotic efflux-pump genes increase the 378 
transcription of their cognate efflux-pumps. This shows that P. aeruginosa is subject 379 
to significant adaptation during the early stages of infection and could have impact on 380 
future treatment strategies. 381 
Conclusions 382 
This study documents gene expression changes in at least three major groups of 383 
genes. The reciprocal nature of the T3SS and the T6SS strongly suggests that the 384 
expression of different virulence factors is needed at different stages of infection. The 385 
initial retS mutation, leading to a chronic infection type, suggests that the first stage of 386 
infection requires protection from the host or competing bacteria with expression of 387 
T6SS and phenazines. However, the later stage with the gacS or gacA mutation, 388 
promoting acute infection behavior, suggests that at some point during infection the 389 
chronic infection behavior is detrimental to the success of the infection. Instead, a 390 
phenotype based on motility and the T3SS to combat the immune system and 391 
disseminate from the initial focus of infection is needed. Furthermore, the increased 392 
expression of denitrification genes in the lineage DK41 suggests that denitrification is 393 
important for the survivability of the P. aeruginosa infection, at least under some 394 
circumstances. Additionally, there is an increase in expression of three operons that 395 
contain efflux pumps across both lineages that is connected to mutations in their 396 
respective regulators suggesting that there is a need for increased efflux of antibiotics. 397 
However, the fact that no further isolates were culturable from the patients, suggests 398 
that the sum of these mutations does not produce a viable phenotype in a CF infection 399 
setting. 400 
  401 
Materials and methods 402 
Cell handling 403 
All strains were grown in LB-Miller (1% NaCl) at 37 °C with shaking at 200 rpm. 404 
RNA extraction and treatment 405 
O/N cultures were diluted 100 times in a conical flask to a total volume of 100 mL 406 
LB. 10 mL of culture was taken per sample at late exponential phase (OD600 = 1), 407 
transferred to conical tubes with 2 mL of stop solution (95% ethanol, 5% phenol), 408 
vortexed thoroughly and left at RT for 5 minutes. The bacteria were pelleted (3500g, 409 
10 min, 4 °C) and the supernatants discarded. The pellets were dissolved in 1 mL of 410 
Trizol each and stored at -80 °C until further use. Total RNA extraction and DNA 411 
removal by treatment with DNase I were performed as described in [32] and RNA 412 
quality was checked on the Agilent Bioanalyzer using the Agilent RNA 6000 Nano 413 
Kit. Ribosomal RNA was depleted using MICROBExpress™ Bacterial mRNA 414 
Enrichment Kit (Ambion) but with a modification for the removal of 5S RNA as 415 
described in [32]. The depletion of rRNA was checked on the Agilent Bioanalyzer 416 
using the Agilent RNA 600 Nano Kit.  417 
Library preparation and sequencing 418 
The libraries were prepared using the TruSeq™ RNA Sample Prep Kit v2 (Illumina), 419 
the size was checked on the Agilent Bioanalyzer using the DNA high sensitivity 420 
assay, the concentration confirmed on Qubit 2.0 Fluorometer, and were sequenced on 421 
the Illumina MiSeq in a 2x150 bp paired-end configuration. The reads were mapped 422 
to the PAO1 reference genome using Rockhopper [33], [34]. Mapping statistics are 423 
found in Table S3. 424 
Protein extraction and sample preparation for MS analysis 425 
Cells were harvested in the late-exponential growth phase (OD600 = 1) by 426 
centrifugation (10 min, 8500 rpm, 4 °C), resuspended in 1 mL 50 mM TE buffer, pH 427 
7.5, and transferred in a 2 mL screw cap micro tube containing 500 µL glass beads 428 
with 0.1 mm diameter. Subsequently, cells were lysed mechanically using the 429 
Precellys 24 homogenizator (PeqLab, Erlangen, Germany; 3 × 30 s at 6,800 rpm). 430 
Cell debris and glass beads were removed by centrifugation (3 x 20 min at 15,000 431 
rpm, 4 °C). Protein concentration of extracts was determined using a ninhydrin-based 432 
assay [35]. Protein extracts (100 µg) were reduced, alkylated and trypsin-digested 433 
(Promega, Fitchburg, WI) as previously described [36]. Prior to liquid 434 
chromatography/ion-mobility spectrometry (LC/IMSE) analysis, samples were 435 
desalted using C18-Stage Tips (Thermo scientific, Waltham, MA) [37] and a 436 
complete tryptic digest of alcohol dehydrogenase of yeast (ADH, Waters, Milford, 437 
MA) was added to a final concentration of 50 fmol/µL. All experiments were carried 438 
out in 3 biological and 3 technical replicates per biological sample.  439 
LC/IMSE data acquisition and analysis 440 
Peptide samples were analyzed with a nanoACQUITY ultraperformance liquid 441 
chromatography (UPLC) system (Waters) coupled to a Synapt G2 mass spectrometer 442 
(Waters), as previously described [38]. Raw data were processed via the ProteinLynx 443 
Global Server (PLGS, Version 2.5.3, Waters) by the Apex3D algorithm including the 444 
following parameters: Chromatographic peak width and MS TOF resolution were set 445 
to automatic, lock mass charge 2 set to 785.8426 Da/e with a lock mass window of 446 
0.25 Da, low energy threshold 200.0 counts, elevated energy threshold 20.0 counts, 447 
intensity threshold 750 counts. The processed data were searched against a 448 
P. aeruginosa PAO1 database containing 11,226 entries (NCBI, version 2012-11-13) 449 
including common laboratory contaminants and the yeast ADH1 sequence. The 450 
following search parameters were used: enzyme type trypsin; 1 fragment ion matched 451 
per peptide, 5 fragment ions matched per protein, 2 peptide matched per protein; 2 452 
missed cleavages allowed; fixed modification: carbamidomethylation C (+57.0215); 453 
variable modifications: deamidation N, Q (+0.9840), oxidation M (+15.9949), 454 
pyrrolidonecarboxylacid N-TERM (-27.9949); the false-discovery rate (FDR) was 455 
5%; and the calibration protein was yeast alchohol dehydrogenase 1. For quantitation 456 
only proteins were considered that were identified in two out of three biological and 457 
technical replicates, respectively (replicate filter). Absolute protein quantification was 458 
achieved using the Hi3 approach [39] with yeast ADH as a reference. Differentially 459 
expressed proteins were identified using one-way ANOVA (p=0.05) in R and the 460 
false discovery rate was controlled by Benjamini-Hochberg procedure. 461 
Transcriptomic data handling 462 
The raw read files were quality checked using FastQC [40]. The expression values 463 
provided by Rockhopper were then used for downstream analysis using custom R-464 
scripts. Both lineages were subjected to ANOVA (p < 0.05) for differential expression 465 
analyses and the false discovery rate was controlled by Benjamini-Hochberg 466 
procedure. 467 
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Supplemental material 628 
 629 
Figure S1. PCA plot of proteomics data. Component 1 explains 39.1% of the variance 630 
and component 2 explains 33.4% of the variance. 631 
 632 
Table S1. Information about and isolates including the patient, date of isolation, the 633 
material of origin of the isolates and the lineage. 634 
Isolate Patient Date 
obtained 
Material Lineage 
R (MRCA) P38F4  1/29/2007  Endolaryngeal suction  DK17 
G P38F4 10/22/2008 Right maxillary sinus DK17 
M P38F4 04/05/2011 Right maxillary sinus DK17 
Y P38F4 04/05/2011 Secretion from the ethmoids DK17 
366 (MRCA) P76M4 01/08/2008 Endolaryngeal suction DK41 
380 P76M4 3/17/2010 Endolaryngeal suction DK41 
364 P76M4 08/22/2012 Sputum sample DK41 
 635 
Table S2ABCD. All mutations in the lineages. 1 represents that the mutation specified 636 
in ‘qry’ is present in the position specified. Type indicates the nature of the mutation. 637 
In the case of single nucleotide polymorphisms, ‘ref’ indicates the base in the 638 
reference genome whereas ‘qry’ indicates the mutation.  639 
Table S2A. All indels that are different between strains R, G, M, and Y of lineage 640 
DK17. 641 
G M R Y position ref qry type locus name product pseudocap 
0 1 0 0 14445 * +TGGATAT Insertion PA0011  probable 2-OH-
lauroyltransferase 
Cell wall / LPS / capsule 
0 0 0 1 14813 * -GCGCGTACCGCTG Deletion PA0011  probable 2-OH-
lauroyltransferase 
Cell wall / LPS / capsule 
0 1 0 0 370459 * -A Intergenic 
Deletion 
PA0328//PA0329 // 55 upstream 
hypothetical 
protein//246 
downstream conserved 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
0 0 0 1 451733 * -ACGAGAACTCGGT Deletion PA0411 pilJ twitching motility 
protein PilJ 
Chemotaxis; Motility & 
Attachment 
0 0 0 1 471602 * -TTGTTCGTCGATAA Deletion PA0424 mexR multidrug resistance 
operon repressor MexR 
Transcriptional regulators 
0 1 1 0 809540 * -C Intergenic 
Deletion 
PA0741//PA0742 // 84 upstream conserved 
hypothetical 
protein//33 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
1 0 1 1 896130 * +TAAA Intergenic 
Insertion 
PA0819//PA0820 // 13 downstream 
hypothetical 
protein//286 upstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
1 0 1 1 959359 * -GT Intergenic 
Deletion 
PA0876//PA0877 // 10 downstream 
probable 
transcriptional 
regulator//124 
downstream probable 
transcriptional 
regulator 
Transcriptional 
regulators//Transcriptional 
regulators 
1 1 0 1 994775 * +CGGGAGTGT Insertion PA0911  hypothetical protein Hypothetical, unclassified, 
unknown 
0 1 0 0 1015471 * +CGTT Insertion PA0928 gacS sensor/response 
regulator hybrid 
Two-component 
regulatory systems 
0 1 0 0 1156537 * -TGGAGCGCCAG Deletion PA1069  hypothetical protein Hypothetical, unclassified, 
unknown 
0 0 1 0 1233279 * +GAGCGCC Intergenic 
Insertion 
PA1141//PA1142 // 148 upstream probable 
transcriptional 
regulator//18 
downstream probable 
transcriptional 
regulator 
Transcriptional 
regulators//Transcriptional 
regulators 
0 1 1 1 1447059 * +CATTCCCCACA Intergenic 
Insertion 
PA1334//PA1335 // 141 upstream probable 
oxidoreductase//167 
downstream probable 
two-component 
response regulator 
Putative 
enzymes//Transcriptional 
regulators; Two-
component regulatory 
systems 
1 1 1 0 1447060 * +ATT Intergenic 
Insertion 
PA1334//PA1335 // 142 upstream probable 
oxidoreductase//166 
downstream probable 
two-component 
response regulator 
Putative 
enzymes//Transcriptional 
regulators; Two-
component regulatory 
systems 
0 0 1 1 1495579 * +CGGAAAAC Intergenic 
Insertion 
PA1377//PA1378 // 87 downstream 
conserved hypothetical 
protein//56 upstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
1 0 1 1 1552312 * +T Insertion PA1425  probable ATP-binding 
component of ABC 
transporter 
Transport of small 
molecules 
0 0 0 1 1681088 * -GCCGGCGAG Deletion PA1544 anr transcriptional 
regulator Anr 
Transcriptional regulators 
0 0 0 0 2263645 * -GTCCATGCCGTTCAT Deletion PA2065 pcoA copper resistance 
protein A precursor 
Adaptation, Protection 
0 0 0 1 1688689 * -AGCCA Deletion PA1551  probable ferredoxin Energy metabolism 
0 1 1 0 1999485 * +CGGTTT Intergenic 
Insertion 
PA1841//PA1842 // 25 downstream 
hypothetical 
protein//27 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
G M R Y position ref qry type locus name product pseudocap 
0 1 0 0 2142950 * +TGGGAAA Intergenic 
Insertion 
PA1958//PA1959 //bacA 61 upstream probable 
transporter//223 
upstream bacitracin 
resistance protein 
Membrane proteins; 
Transport of small 
molecules//Cell wall / LPS / 
capsule; Adaptation, 
Protection; Antibiotic 
resistance and 
susceptibility 
1 0 0 1 2142952 * +GGAAAAA Intergenic 
Insertion 
PA1958//PA1959 //bacA 63 upstream probable 
transporter//221 
upstream bacitracin 
resistance protein 
Membrane proteins; 
Transport of small 
molecules//Cell wall / LPS / 
capsule; Adaptation, 
Protection; Antibiotic 
resistance and 
susceptibility 
1 1 0 1 2251287 * +C Insertion PA2057  hypothetical protein Hypothetical, unclassified, 
unknown 
0 0 0 0 2722126 * -A Intergenic 
Deletion 
PA2425//PA2426 pvdG//pvdS 596 upstream 
PvdG//48 upstream 
sigma factor PvdS 
Adaptation, 
Protection//Transcriptional 
regulators 
1 1 0 1 2379882 * +AG Insertion PA2160  probable glycosyl 
hydrolase 
Putative enzymes 
1 1 0 1 2379888 * +A Insertion PA2160  probable glycosyl 
hydrolase 
Putative enzymes 
1 1 0 1 2379890 * +CATTGAGGA Insertion PA2160  probable glycosyl 
hydrolase 
Putative enzymes 
1 1 0 1 2379890 * +GA Insertion PA2160  probable glycosyl 
hydrolase 
Putative enzymes 
1 1 0 1 2379891 * +T Insertion PA2160  probable glycosyl 
hydrolase 
Putative enzymes 
1 1 0 1 2400365 * +GCG Intergenic 
Insertion 
PA2178//PA2179 // 85 upstream 
hypothetical 
protein//290 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
0 0 0 1 2400594 * +TCC Intergenic 
Insertion 
PA2178//PA2179 // 314 upstream 
hypothetical 
protein//61 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
0 1 1 0 2571782 * +G Insertion PA2330  hypothetical protein Hypothetical, unclassified, 
unknown 
1 1 1 0 2623258 * -GT Deletion PA2371  probable ClpA/B-type 
protease 
Translation, post-
translational modification, 
degradation 
0 0 0 1 2730153 * -GCCAGCCCGCCGG Deletion PA2434  hypothetical protein Hypothetical, unclassified, 
unknown 
1 1 0 1 2806290 * +AACGAAT Insertion PA2490  conserved hypothetical 
protein 
Hypothetical, unclassified, 
unknown 
1 0 0 0 2864118 * -G Intergenic 
Deletion 
PA2535//PA2536 // 180 downstream 
probable 
oxidoreductase//51 
downstream probable 
phosphatidate 
cytidylyltransferase 
Putative enzymes//Fatty 
acid and phospholipid 
metabolism 
0 0 0 1 2926331 * -T Deletion PA2586 gacA response regulator 
GacA 
Transcriptional regulators 
0 1 1 0 3087585 * +AATGTAGTGGTC Intergenic 
Insertion 
PA2729//PA2730 // 94 downstream 
hypothetical 
protein//1075 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
1 0 0 1 3087587 * +TGTAGTGGT Intergenic 
Insertion 
PA2729//PA2730 // 96 downstream 
hypothetical 
protein//1073 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
1 1 0 0 3249252 * +C Insertion PA2894  hypothetical protein Hypothetical, unclassified, 
unknown 
1 1 0 1 3496464 * -GCAGGTCGGT Deletion PA3115 fimV Motility protein FimV Membrane proteins; 
Motility & Attachment 
1 1 1 0 3526714 * +TCTG Intergenic 
Insertion 
PA3141//PA3142 wbpM// 36 upstream nucleotide 
sugar 
epimerase/dehydratase 
WbpM//715 
downstream 
hypothetical protein 
Putative enzymes; 
Membrane proteins; Cell 
wall / LPS / 
capsule//Related to phage, 
transposon, or plasmid 
G M R Y position ref qry type locus name product pseudocap 
0 0 0 1 3557172 * +CCTCGACTT Insertion PA3168 gyrA DNA gyrase subunit A DNA replication, 
recombination, 
modification and repair 
0 1 1 0 3618697 * +GGCGGA Intergenic 
Insertion 
PA3230//PA3231 // 230 upstream 
conserved hypothetical 
protein//29 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Membrane 
proteins 
1 1 0 0 3682825 * +GGTTTCAGGCGT Insertion PA3290  hypothetical protein Hypothetical, unclassified, 
unknown 
0 1 0 0 3694006 * +CGCG Insertion PA3297  probable ATP-
dependent helicase 
Transcription, RNA 
processing and 
degradation 
0 0 1 0 3820916 * +CCA Intergenic 
Insertion 
PA3414//PA3415 // 24 downstream 
hypothetical 
protein//469 
downstream probable 
dihydrolipoamide 
acetyltransferase 
Hypothetical, unclassified, 
unknown//Energy 
metabolism 
1 0 1 0 3820918 * +ATCG Intergenic 
Insertion 
PA3414//PA3415 // 26 downstream 
hypothetical 
protein//467 
downstream probable 
dihydrolipoamide 
acetyltransferase 
Hypothetical, unclassified, 
unknown//Energy 
metabolism 
1 1 1 0 3974147 * +GT Intergenic 
Insertion 
PA3547//PA3548 algL//algI 30 downstream 
poly(beta-d-
mannuronate) lyase 
precursor AlgL//212 
upstream alginate o-
acetyltransferase AlgI 
Cell wall / LPS / capsule; 
Adaptation, Protection; 
Secreted Factors (toxins, 
enzymes, alginate)//Cell 
wall / LPS / capsule; 
Adaptation, Protection; 
Secreted Factors (toxins, 
enzymes, alginate) 
0 0 1 0 4166949 * +GTA Insertion PA3721 nalC NalC Transcriptional regulators; 
Antibiotic resistance and 
susceptibility 
1 0 1 1 4417080 * +AA Insertion PA3939  hypothetical protein Hypothetical, unclassified, 
unknown 
1 1 0 1 4432946 * +CCC Insertion PA3952  hypothetical protein Hypothetical, unclassified, 
unknown 
1 0 0 0 4493463 * +C Insertion PA4013  conserved hypothetical 
protein 
Membrane proteins 
1 1 1 0 4714800 * +GATC Insertion PA4211 phzB1 probable phenazine 
biosynthesis protein 
Secreted Factors (toxins, 
enzymes, alginate) 
0 0 0 1 5026059 * +GG Insertion PA4491  conserved hypothetical 
protein 
Hypothetical, unclassified, 
unknown 
0 1 0 0 5155826 * -CCACCGCGA Deletion PA4600 nfxB transcriptional 
regulator NfxB 
Transcriptional regulators 
0 0 1 0 5206144 * -GGCGATG Intergenic 
Deletion 
PA4636//PA4637 // 57 downstream 
hypothetical 
protein//64 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
0 1 0 0 5312996 * +G Insertion PA4730 panC pantoate--beta-alanine 
ligase 
Biosynthesis of cofactors, 
prosthetic groups and 
carriers 
1 1 0 1 5384501 * +AAT Insertion PA4798  hypothetical protein Hypothetical, unclassified, 
unknown 
1 1 0 0 5387754 * +AGGC Intergenic 
Insertion 
PA4802//PA4802.1 // 32 downstream tRNA-
Sec//12 downstream 
tRNA-Sec 
Hypothetical, unclassified, 
unknown//Non-coding 
RNA gene 
1 1 0 1 5775356 * -C Intergenic 
Deletion 
PA5125//PA5126 ntrC// 550 downstream two-
component response 
regulator NtrC//263 
downstream 
hypothetical protein 
Transcriptional regulators; 
Two-component 
regulatory 
systems//Hypothetical, 
unclassified, unknown 
1 0 1 1 5810046 * +T Intergenic 
Insertion 
PA5160.1//PA5161 //rmlB 1 downstream tRNA-
Thr//235 upstream 
dTDP-D-glucose 4,6-
dehydratase 
Non-coding RNA 
gene//Carbon compound 
catabolism; Cell wall / LPS 
/ capsule 
1 0 1 1 5930755 * +GCCTGC Insertion PA5266  conserved hypothetical 
protein 
Hypothetical, unclassified, 
unknown 
1 0 0 0 6154750 * +TC Intergenic 
Insertion 
PA5464//PA5465 // 74 downstream 
hypothetical 
protein//34 
downstream 
hypothetical protein 
Hypothetical, unclassified, 
unknown//Hypothetical, 
unclassified, unknown 
Table S2B. All single nucleotide polymorphisms that are different between strains R, 642 
G, M, and Y of lineage DK17. 643 
G M R Y position ref qry type locus name product pseudocap 
1 0 1 1 499765 G A Intergenic PA0444//PA0445 // 62 downstream N-
carbamoyl-beta-alanine 
amidohydrolase//339 
downstream probable 
transposase 
Nucleotide biosynthesis 
and 
metabolism//Related to 
phage, transposon, or 
plasmid 
0 0 0 1 1665536 C T Missense PA1528 zipA cell division protein ZipA Cell division 
0 1 0 0 1744763 C T Silent PA1601  probable aldehyde 
dehydrogenase 
Putative enzymes 
1 1 0 1 2212705 A C Missense PA2020  probable transcriptional 
regulator 
Transcriptional 
regulators 
1 1 0 1 2455991 A G Missense PA2232 pslB PslB Cell wall / LPS / capsule 
0 0 0 1 2458028 C A Silent PA2234 pslD PslD Cell wall / LPS / capsule; 
Transport of small 
molecules 
1 1 0 1 2799381 G A Missense PA2480  probable two-
component sensor 
Two-component 
regulatory systems 
0 0 0 1 4034375 G A Silent PA3598  conserved hypothetical 
protein 
Hypothetical, 
unclassified, unknown 
1 1 0 1 4311423 C G Missense PA3850  hypothetical protein Hypothetical, 
unclassified, unknown 
0 0 0 1 4768891 A G Silent PA4265 tufA elongation factor Tu Translation, post-
translational 
modification, 
degradation 
0 0 0 1 4768975 T C Silent PA4265 tufA elongation factor Tu Translation, post-
translational 
modification, 
degradation 
1 1 0 1 5453680 G T Nonsense PA4856 retS RetS (Regulator of 
Exopolysaccharide and 
Type III Secretion) 
Two-component 
regulatory systems 
Table S2C. All indels that are different between strains 366, 380, and 364 of lineage 644 
DK41. 645 
364 366 380 position ref qry type locus name product pseudocap 
1 0 0 340031 * -AGAAGA Deletion PA0301 spuE polyamine 
transport 
protein 
Transport of small 
molecules 
1 0 1 398135 * -A Intergenic 
Deletion 
PA0353//PA0
354 
ilvD// 241 upstream 
dihydroxy-acid 
dehydratase//
88 
downstream 
conserved 
hypothetical 
protein 
Biosynthesis of 
cofactors, prosthetic 
groups and carriers; 
Amino acid 
biosynthesis and 
metabolism//Hypoth
etical, unclassified, 
unknown 
0 1 0 453109 * +A Insertion PA0411 pilJ twitching 
motility 
protein PilJ 
Chemotaxis; Motility 
& Attachment 
1 0 1 471696 * -T Deletion PA0424 mexR multidrug 
resistance 
operon 
repressor 
MexR 
Transcriptional 
regulators 
1 0 1 892604 * -CAG Deletion PA0814  conserved 
hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown 
1 0 0 949337 * -T Deletion PA0868  conserved 
hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown 
1 0 0 1015721 * +CG Insertion PA0928 gacS sensor/respon
se regulator 
hybrid 
Two-component 
regulatory systems 
364 366 380 position ref qry type locus name product pseudocap 
1 1 0 1249854 * +A Intergenic 
Insertion 
PA1154//PA1
155 
//nrd
B 
302 upstream 
conserved 
hypothetical 
protein//53 
downstream 
NrdB, tyrosyl 
radical-
harboring 
component of 
class Ia 
ribonucleotide 
reductase 
Hypothetical, 
unclassified, 
unknown//Nucleotid
e biosynthesis and 
metabolism 
1 0 0 1270409 * -AGGCGAGGGCGA Deletion PA1170  conserved 
hypothetical 
protein 
Membrane proteins 
1 0 0 1366984 * -G Deletion PA1259  hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown 
0 0 1 2235372 * -TT Intergenic 
Deletion 
PA2042//PA2
043 
// 64 
downstream 
probable 
transporter 
(membrane 
subunit)//57 
upstream 
hypothetical 
protein 
Transport of small 
molecules//Hypothet
ical, unclassified, 
unknown 
0 1 0 2637061 * -TG Deletion PA2385 pvdQ 3-oxo-C12-
homoserine 
lactone acylase 
PvdQ 
Adaptation, 
Protection 
1 1 0 2756236 * -GG Deletion PA2455  hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown 
1 0 1 2807546 * -C Deletion PA2492 mexT transcriptional 
regulator 
MexT 
Transcriptional 
regulators 
0 1 0 2810971 * -C Deletion PA2494 mexF Resistance-
Nodulation-
Cell Division 
(RND) 
multidrug 
efflux 
transporter 
MexF 
Transport of small 
molecules; 
Membrane proteins; 
Antibiotic resistance 
and susceptibility 
1 1 0 3129137 * +A Intergenic 
Insertion 
PA2770//PA2
771 
// 66 upstream 
hypothetical 
protein//592 
upstream 
conserved 
hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown//Hypotheti
cal, unclassified, 
unknown 
0 1 1 3486413 * -A Intergenic 
Deletion 
PA3105//PA3
106 
xcpQ/
/ 
84 
downstream 
general 
secretion 
pathway 
protein D//3 
downstream 
probable 
short-chain 
dehydrogenas
e 
Protein 
secretion/export 
apparatus//Putative 
enzymes 
0 1 0 3514799 * -AAT Intergenic 
Deletion 
PA3133.1//PA
3133.2 
// 2 upstream 
tRNA-Glu//45 
downstream 
tRNA-Ala 
Non-coding RNA 
gene//Non-coding 
RNA gene 
1 0 0 3694826 * -GCCGCGCCTCG Deletion PA3297  probable ATP-
dependent 
helicase 
Transcription, RNA 
processing and 
degradation 
0 1 1 3780318 * -CCCACAACGC Intergenic 
Deletion 
PA3371//PA3
372 
// 6 downstream 
hypothetical 
protein//43 
downstream 
conserved 
hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown//Transport 
of small molecules 
364 366 380 position ref qry type locus name product pseudocap 
1 1 0 4009340 * +CA Intergenic 
Insertion 
PA3577//PA3
578 
// 289 upstream 
hypothetical 
protein//202 
downstream 
conserved 
hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown//Hypotheti
cal, unclassified, 
unknown 
1 0 0 4607471 * +GCCG Intergenic 
Insertion 
PA4118//PA4
119 
//aph 17 
downstream 
hypothetical 
protein//107 
downstream 
aminoglycosid
e 3'-
phosphotransf
erase type IIb 
Hypothetical, 
unclassified, 
unknown//Antibiotic 
resistance and 
susceptibility 
1 0 1 4714801 * +ATCGAA Insertion PA4211 phzB1 probable 
phenazine 
biosynthesis 
protein 
Secreted Factors 
(toxins, enzymes, 
alginate) 
1 0 0 4865466 * -A Deletion PA4336  conserved 
hypothetical 
protein 
Hypothetical, 
unclassified, 
unknown 
0 1 0 4896208 * -A Deletion PA4367 bifA BifA Motility & 
Attachment; Cell wall 
/ LPS / capsule 
1 0 1 5452961 * -CTTCCGCGGCA Deletion PA4856 retS RetS 
(Regulator of 
Exopolysaccha
ride and Type 
III Secretion) 
Two-component 
regulatory systems 
1 0 1 5677001 * -AGCGACAGTT Deletion PA5040 pilQ Type 4 fimbrial 
biogenesis 
outer 
membrane 
protein PilQ 
precursor 
Motility & 
Attachment 
0 1 0 5743831 * -GCACGTGTA Deletion PA5100 hutU urocanase Amino acid 
biosynthesis and 
metabolism 
0 0 1 5807183 * -CAACAGCGAAA Deletion PA5159  multidrug 
resistance 
protein 
Transport of small 
molecules; Antibiotic 
resistance and 
susceptibility 
1 0 1 5942472 * +C Insertion PA5277 lysA diaminopimela
te 
decarboxylase 
Amino acid 
biosynthesis and 
metabolism 
1 0 1 5986292 * -G Intergenic 
Deletion 
PA5316.1//PA
5317 
// 123 
downstream 
//182 
upstream 
probable 
binding 
protein 
component of 
ABC dipeptide 
transporter 
Non-coding RNA 
gene//Transport of 
small molecules 
0 1 0 5986294 * -C Intergenic 
Deletion 
PA5316.1//PA
5317 
// 125 
downstream 
//180 
upstream 
probable 
binding 
protein 
component of 
ABC dipeptide 
transporter 
Non-coding RNA 
gene//Transport of 
small molecules 
1 0 0 6120645 * -GTGAAGGGGTG Deletion PA5437  probable 
transcriptional 
regulator 
Transcriptional 
regulators 
Table S2D. All single nucleotide polymorphisms that are different between strains 646 
366, 380, and 364 of lineage DK41. 647 
364 366 380 position ref qry type locus name product pseudocap 
1 0 1 2212812 G T Missense PA202
0 
 probable 
transcriptional 
Transcriptional regulators 
regulator 
1 0 1 2808453 G A Missense PA249
2 
mexT transcriptional 
regulator MexT 
Transcriptional regulators 
1 0 0 4043670 G A Missense PA360
9 
potC polyamine transport 
protein PotC 
Membrane proteins; Transport of 
small molecules 
0 1 0 5021956 C T Silent PA448
9 
 conserved 
hypothetical protein 
Hypothetical, unclassified, 
unknown 
1 0 0 5730325 G A Silent PA509
0 
 conserved 
hypothetical protein 
Hypothetical, unclassified, 
unknown 
1 0 0 5730340 T C Silent PA509
0 
 conserved 
hypothetical protein 
Hypothetical, unclassified, 
unknown 
 648 
Table S3. Mapping statistics 649 
Sample R1 R2 G1 G2 M1 M2 Y1 Y2 
Total reads 4101031 3100021 2750399 3060869 3092746 5674693 3966006 4295983 
Mapped 
reads 
3909999 
(95%) 
2967636 
(96%) 
2583598 
(94%) 
2924255 
(96%) 
2943686 
(95%) 
5351526 
(94%) 
3799002 
(96%) 
3873508 
(90%) 
 650 
Sample 366-1 366-2 380-1 380-2 364-1 364-2 
Total reads 4560412 3669173 4039980 4013697 3355139 3384675 
Mapped reads 4189811 
(92%) 
3383537 
(92%) 
3666251 
(91%) 
3681479 
(92%) 
3050809 
(91%) 
3117126 
(92%) 
Table S4A. Identified and quantified proteins in DK17 with their predicted 651 
localization by PSORTb. 652 
Too long to insert in thesis. 653 
Table S4B. Identified and quantified proteins in DK41 with their predicted 654 
localization by pSORTb. 655 
Too long to insert in thesis. 656 
Table S5A. Differentially expressed transcripts in DK17 as determined by ANOVA 657 
(p < 0.05) 658 
Too long to insert in thesis. 659 
Table S5B. Differentially expressed transcripts in DK41as determined by ANOVA (p 660 
< 0.05) 661 
Too long to insert in thesis. 662 
Table S5C. Differentially abundant proteins in DK17 as determined by ANOVA (p < 663 
0.05) 664 
Too long to insert in thesis. 665 
Table S5D. Differentially abundant protein in DK41 as determined by ANOVA (p < 666 
0.05) 667 
Too long to insert in thesis. 668 
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Summary 8 
Pseudomonas aeruginosa is a significant cause of morbidity and mortality in cystic fibrosis (CF) patients due 9 
to P. aeruginosa establishing chronic infection in the CF airways. During this time, P. aeruginosa will 10 
evolve and adapt to the new environment through the fixation of mutations in its genome. The common 11 
evolutionary trajectories include loss of virulence factors, mucoidy, increased biofilm formation or mucoidy, 12 
and increased antibiotic resistance. This evolution is commonly caused by mutations in regulatory genes, 13 
which can have large phenotypic consequences. Here the specific effects of mutation in the retS-gacS-gacA-14 
rsmA-rsmYZ are investigated, as these occur in a sequential manner where retS mutates before gacS. Two 15 
lineages of P. aeruginosa (DK17 and DK41) isolated from the first four years of infection of the CF airways 16 
in two patients are examined on a transcriptomic level (RNA-sequencing). Additionally, the mutated alleles 17 
of retS and gacS are moved into the earlier isolated strains not containing these mutations. This enabled the 18 
investigation of the effects caused only by retS and/or gacS mutations without the noise caused by the 19 
residual mutations present in the clinical isolates. Furthermore, the non-mutated alleles from the first isolates 20 
of DK17 and DK41 were also moved to the later isolates in order to examine the effects of the residual 21 
mutations. In the purely clinical isolates, temporal expression of virulence factors such as the Type III 22 
secretion system (T3SS), the Type VI secretion system (T6SS), and phenazine biosynthesis operons was 23 
observed. However, the mutations not occurring in the retS-gacS-gacA-rsmA-rsmYZ signalling pathway also 24 
have effects on the expression of virulence factors. In one lineages the residual mutations accentuate the 25 
effects of retS/gacS mutations causing increased expression of the phenazines biosynthesis operon and in the 26 
other lineage the opposite occurs and the residual mutations counteract the effects leading to lower 27 
expression of the phenazines biosynthesis operons.  28 
Introduction 29 
Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis (CF) patients. The 30 
bacterial infections of the CF airways may persist for a lifetime with the same P. aeruginosa lineage giving 31 
ample time to evolve and adapt to the new environment of the CF airways [1]. This environment is not 32 
perfectly characterized, but stress factors proposed to exist in the CF airways environment include other 33 
microorganisms [2], antibiotics [3], osmotic stress [4], oxidative stress [5], and nitrosative stress [6]. 34 
P. aeruginosa has a relatively large genome (PAO1: 6.26 mb) and has 526 genes classified as involved in 35 
transcription [7], meaning that at least 9.2% of its 5688 annotated genes probably have some sort of 36 
regulatory function. Mutations of regulators can lead to quick adaptation to new environments and it has 37 
been shown that regulators are indeed focal points of mutations in sequential P. aeruginosa during infection 38 
of the CF airways [8]–[10]. Furthermore, the genome contains a large amount of virulence factors including 39 
but not limited to the type III secretion system (T3SS), three clusters of type VI secretion system (H1-T6SS, 40 
H2-T6SS, and H3-T6SS) [11], [12], pyocyanin and other phenazines [13], [14]. The regulation of these 41 
virulence factors is interconnected and complex and relies on various environmental cues [15], e.g. 42 
temperature [16] and various stresses. 43 
The retS-gacS-gacA-rsmA-rsmYZ signaling pathway reciprocally regulates genes that have been attributed to 44 
either chronic or acute infection modes. The regulon encompasses around 500 genes [17] and is regulated 45 
through an intricate system of a two-component system (TCS) (GacA/GacS), small RNAs (sRNAs) 46 
(RsmYZ), RsmA, and at least three histidine kinases, RetS, LadS, and PA1611 that modulate the activity of 47 
the TCS [18]–[20]. RetS, a hybrid sensor kinase, inhibits the autophosphorylation of dimeric GacS, which in 48 
its active phosphorylated and dimeric state, will activate GacA, a transcriptional regulator. The sole function 49 
of GacA is to activate transcription of the two sRNAs, RsmY and RsmZ. These sRNAs inhibit the function 50 
of RsmA by binding directly to it and thereby altering its function. The chronic infection mode is 51 
characterized by expression of the type III secretion system, type IV pili biogenesis genes, and iron 52 
homeostasis genes [17], whereas the chronic state is characterized by expression of some of the type VI 53 
secretion system clusters, phenazine biosynthesis genes, and the pel/psl biofilm operons. This regulation 54 
occurs through a combination of direct and indirect regulation at both the transcriptional and post-55 
transcriptional levels through RsmA [17]. However, the signal that activates this system is not yet known. 56 
Previous studies have found this system to be a hotspot for mutations during infection of the CF airways [9], 57 
[21]. Curiously, in the study by Marvig, et al., [9] mutations in this system occurred in a specific order with 58 
retS always mutating before the gacS, gacA or rsmA genes.  59 
The advent of next generation sequencing has enabled the rapid determination of the entire RNAome [22], 60 
[23] with relative ease through RNA-sequencing (RNA-seq), providing a snapshot of the transcriptional 61 
landscape of the desired microbe at a certain point in time. This has made it possible to study transcriptomic 62 
changes at an unprecedented level of detail, opening up a new world of understanding of cell biology and 63 
physiology. The process involves growing the culture, extracting RNA, converting to cDNA, and sequencing 64 
on a next-gen platform. 65 
Here the effects of spontaneous mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway in clinical 66 
isolates of the P. aeruginosa lineages, DK17 and DK41, are investigated using transcriptomics by RNA-seq. 67 
Initially, we examine the transcriptomes of six isolates in total from two lineages containing multiple 68 
mutations in various genes, but also what appears to be contingent mutations in the retS-gacS-gacA-rsmA-69 
rsmYZ signaling pathway, meaning that mutations appear in a specific order in this system (first retS and 70 
later gacS) during infection of the CF airways. Hereafter, we first moved the mutated version of retS into the 71 
“wild type” strains of DK17 and DK41 (R and 366, respectively), followed by a second event in which we 72 
also inserted the mutated version of gacS in order to examine the specific effects caused by the mutations. 73 
Afterwards, we moved the “wild-type” versions of these genes into the clinical isolates with the mutated 74 
versions of the same genes to determine the effects of the mutations that do not occur in this signaling 75 
pathway (in this called ‘residual evolution’. Differences in evolution were observed in the DK17 and DK41 76 
lineages. In DK17 there was an increased expression of the phenazine biosynthesis operons phz1 and phz2 77 
caused by both the retS-mutation in the signaling pathway and the residual mutations. However, in DK41 78 
only the retS-mutation caused increased expression of these operons, whereas the residual evolution caused 79 
reduced expression of the operons, effectively cancelling out the effects of each other in the purely clinical 80 
isolate. 81 
This work increases the knowledge on the evolution and adaptation of P. aeruginosa in the CF airways and 82 
shows that single mutation genomic analysis may not be sufficient to accurately describe the possibly 83 
convergent evolutionary trajectories found in clinical P. aeruginosa isolates.  84 
Results 85 
Strains and allelic replacements 86 
The strains used in this study have been isolated from two young CF patients. The DK17 isolates originate 87 
from a female patient born in 1996 with the first isolate (R) being from early 2007, the middle (G) from later 88 
2008, and the last from the middle of 2011. The DK41 isolates originate from a male patient born in 2001 89 
with the first isolate (366) being from the middle of 2008, the middle isolate (380) from early 2010, and the 90 
last isolate (364) being from the middle of 2012. Both lineages contain what appear to be contingent 91 
mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway, meaning that in both lineages a strain 92 
without mutations in this system infects the patients. After approximately two years, a retS-mutation appears 93 
in the population and subsequently, after approximately two more years, a gacS-mutation appears. However, 94 
during this period many other residual mutations also appear. In order to examine the effects of the mutations 95 
in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway, both the functional and mutated versions of retS and 96 
gacS were moved between these clinical isolates (Figure 1A+B). 97 
Transcriptomic evolution of clinical isolates  98 
All cells were grown to late exponential phase in LB medium and RNA was harvested. cDNA libraries were 99 
prepared and sequenced on Illumina NextSeq. The reads were mapped and quantified to the genome of P. 100 
aeruginosa PAO1 and were checked for differential expression (2-fold, p < 0.05). Initially, we examined the 101 
transcriptomic evolution of the clinical P. aeruginosa isolates, meaning that we were investigating not only 102 
the effects of the mutations in retS-gacS-gacA-rsmA-rsmYZ signaling pathway, but also the residual 103 
mutations. The initial step of evolution occured over a period of about two years for both DK17 and DK41, 104 
where both lineages evolved a mutation in retS, resulting in strains G and 380, respectively. In DK17, a 105 
single-nucleotide polymorphism occured in retS causing a premature stop-codon in the middle of the gene, 106 
likely leading to loss of function. In DK41, an 11-bp deletion occured about one third into the genes, leading 107 
to a frameshift and likely loss-of-function. Comparing the ‘wild-type’ and retS-mutant clinical isolates of 108 
both lineages, we found that 203 common genes were differentially expressed (2-fold change, p < 0.05) 109 
between both lineages. Surprisingly, only 78 of these were differentially expressed in the same direction, 110 
meaning that the remaining 135 genes were differentially expressed in opposite direction. Only 25 showed 111 
decreased expression in DK17, whereas 102 showed decreased expression in DK41. Some genes of the hcp 112 
Secretion Island-I-encoded type VI secretion system (H1-T6SS) (PA0070-PA0091) [12] had increased 113 
expression in both retS mutants (2-8-fold). The H2-T6SS (PA1656-1671) [24] also had increased expression 114 
of 2-10-fold. However, there is no evidence of differential expression of the H3-T6SS (PA2359-PA2373) 115 
[25], fitting with reports that this system is not regulated by RetS [25], [26]. Furthermore, the galactophilic 116 
lectin, lecA [27] (PA2570), show 14-fold and 6-fold increased expression in DK17 and DK41, respectively. 117 
Surprisingly, none of the type III secretion system (PA1690-PA1725) genes were found to be differentially 118 
expressed in both lineages, even if they have been shown to be regulated by the retS-gacS-gacA-rsmA-rsmYZ 119 
signaling pathway [20]. The phz1 (PA4210-PA4216) and phz2 (PA1899-PA1905) phenazine biosynthetic 120 
operons have also been reported to be regulated directly by RsmA [28]. However, differential expression was 121 
only observed in DK17, where both the phz1 and phz2 operons showed a 4-16-fold increased expression in 122 
the retS-mutant, consistent with observations of green pigmentation during growth (data not shown). 123 
Later in the infection process, we observed that both DK17 and DK41 acquire an additional mutation in 124 
gacS, the next step in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway, resulting in strains M and 364, 125 
respectively. These mutations were again likely loss-of-function mutations, as they were a 4-bp insertion and 126 
a 2-bp insertion in DK17 and DK41, respectively. The double mutants had 100 genes in common that were 127 
differentially expressed when compared with the previous single retS-mutants in the lineages, G and 380. In 128 
this case, all 100 genes were differentially expressed in the same direction; 93 showed decreased expression 129 
and 7 showed increased expression. Given the reciprocal nature of the retS-gacS-gacA-rsmA-rsmYZ 130 
signaling pathway [29], [30], it would be expected that the H1-T6SS and H2-T6SS operons showed 131 
decreased expression in the retS, gacS-mutants. Indeed, this was the case as the H1-T6SS is under expressed 132 
14-fold in both lineages and the H2-T6SS is under expressed 11-fold. Also the APR-type I secretion system 133 
(PA1245-PA1249) [31], [32] was under expressed 4-fold in both lineages. Interestingly, again the phz1 and 134 
phz2 operons were only found to be differentially expressed in DK17 showing a 32-fold under expression for 135 
both operons. 136 
Mutations in retS and gacS cause large scale transcriptional changes 137 
In order to determine the effects of only the retS and gacS mutations in the genetic background of both 138 
lineages, we replaced first the retS gene of the ‘wild-type’ of both lineages with the mutated versions from 139 
the clinical strains, resulting in strains RRM and 366RM, and subsequently also replaced the gacS genes with 140 
their respective mutated versions, resulting in strains RRGM and 366RGM. Comparing strains R and 366 with 141 
the RRM and 366RM, we identified 497 genes that were commonly differentially expressed in both lineages, 142 
294 more than between the clinical isolates. This suggests that the other mutations that occured alongside the 143 
retS-mutations in the clinical isolates made the effects of the retS-mutations less pronounced through 144 
epistasis. Furthermore, 387 of these genes were differentially expressed in the same direction with 436 and 145 
376 genes showing increased expression in DK17 and DK41, respectively.  146 
The H1-T6SS operon was overexpressed in both lineages (4-fold) in the retS-mutants. Also the H2-T6SS 147 
operon showed increased expression; 6-fold in DK17, and 16-fold in DK41. Surprisingly, while the phz1 and 148 
phz2 operons did not show any differential expression from strain 366 to 380 for DK41, they did in the 149 
‘wildtype’ with the mutated retS, 366 vs 366RM. In fact, DK17 showed a 4-fold increased expression of phz1 150 
operon and 6-fold of the phz2 operon, whereas DK41 showed a 5-fold and 8-fold increased expression, 151 
respectively. This suggests that some of the other mutations in the clinical DK41 retS-isolate, 380, had an 152 
effect on expression of the phz1 and phz2 operons and that differential expression of these was selected 153 
against. Another observation that was not observed in the clinical isolates, was in an increase of expression 154 
of rpoS (PA3622), the sigma factor associated with stationary phase/stress response and regulation of 155 
quorum sensing [33], [34]. The differential expression of rpoS could be associated with the aggregation seen 156 
during growth (not shown), since this could be expected to limit nutrient uptake of the bacteria, and would be 157 
expected to have a big influence on the transcriptome of P. aeruginosa. In line with this, the expression of 158 
rhlR (PA3477), the transcriptional regulator of the rhlAB operon (PA3478-9) [35], and the rhlAB operon 159 
itself, the genes responsible for the biosynthesis of rhamnolipids, showed a 20-fold increased expression in 160 
DK17 and 7-fold increased expression in DK41 in strains RRM and 366RM compared to R and 366, 161 
respectively. A 20-fold increase in expression of lasA (PA1871) and lasB (PA3724) was also observed in 162 
both lineages, along with a 2-3-fold increase in expression of lasR (PA1430), their transcriptional regulator 163 
[36]. No differential expression of the T3SS was observed, suggesting that either this system is not 164 
controlled by the retS-gacS-gacA-rsmA-rsmYZ signaling pathway in these lineages or that the conditions, in 165 
which the strains were grown, were not conducive to the expression of the T3SS. 166 
Interestingly, some of the genes that were not differentially expressed in the same direction are the genes of 167 
the atp-operon (PA5553-PA5561), encoding the subunits of the ATP synthase. In DK17, they showed a 2.5-168 
fold increase in expression whereas they showed a 6-fold decreased expression in DK41.   169 
After introducing the gacS mutations into the RRM and 366RM (resulting in strains RRGM and 366RGM, 170 
respectively), no fewer than 1447 genes were differentially expressed commonly between the lineages, 171 
comprising just about one third of the genome of P. aeruginosa when comparing RRM with RRGM and 172 
366RM with 366RGM. Surprisingly, 1425 of these were differentially expressed in the same direction. In both 173 
lineages, 813 of these showed increased expression whereas 612 showed decreased expression. These 174 
numbers seem exceedingly high, however considering the reciprocal nature of the retS-gacS-gacA-rsmA-175 
rsmYZ signaling pathway regulating around 500 genes [17], the aggregation of retS-mutants (not shown), 176 
and the increased expression of rpoS of RRM and 366RM, regulating 772 genes [34], it could be possible. 177 
Furthermore, it turns out that rpoS was expressed at a 3-fold and 4-fold lower level in RRGM and 366RGM, 178 
respectively. Additionally, rpoD, the principal sigma-factor [37], was expressed at a 2-fold and 3-fold higher 179 
level for RRG and 366RG, respectively. Taking all this into account, it is not unlikely that this would lead to 180 
a complete lifestyle change for P. aeruginosa and thus massive transcriptomic changes.  181 
In the double mutants, RRGM and 366RGM, compared to the ‘wild-types’ with retS-mutations, RRM and 182 
366RM, a 14-fold and an 11-fold decrease in expression was observed for the H1-T6SS for DK17 and DK41, 183 
respectively. Also the second cluster, H2-T6SS, showed 38-fold and 54-fold decrease in expression for 184 
DK17 and DK41, respectively. Interestingly, the T3SS cluster was overexpressed in these strains with a 12-185 
fold higher expression in both lineages. The phz1 and phz2 operons were differentially regulated with a much 186 
lower expression in the double mutants compared to the RRM and 366RM. DK17 showed 72-fold lower 187 
expression of the phz2 operon, whereas DK41 showed a 29-fold decrease. A similar pattern was observed for 188 
the phz1 operon, where it was expressed 63-fold lower in DK17 and 20-fold lower in DK41.  189 
Another observation is that the cluster containing the ribosomal proteins and RNA polymerase genes 190 
(PA4277-4237) is upregulated 7-fold on average in DK17 and 4-fold on average in DK41, possibly 191 
suggesting increased transcriptional activity, which could be linked to the increased expression of rpoD and 192 
decreased expression of rpoS.  193 
Residual mutations also affect the expression of virulence factors 194 
In order to determine the effects of residual evolution, the evolution/transcriptomic changes not caused by 195 
mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway, we also moved the ‘wild-type’ versions of 196 
retS and gacS into the clinical isolates (G, M, 380, and 364) containing the mutated version of the 197 
aforementioned genes of the respective lineages. This resulted in GRWT (G with ‘wild-type’ retS), MRGWT 198 
(M with ‘wild-type’ retS and gacS), 380RWT (380 with ‘wild-type’ retS), and 364RGWT (364 with ‘wild-type’ 199 
retS and gacS). Examining only the genes that were differentially expressed in both lineages for the strains R 200 
and 366 versus strains GR and 380R, we observed that 413 genes are differentially expressed with 349 being 201 
in the same direction. Surprisingly, we observed that some of the genes that were differentially expressed in 202 
RRM and 366RM were also differentially expressed in the clinical isolates, strains GRWT and 380RWT, without 203 
the mutation in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway. For example, nine genes in the H1-T6SS 204 
cluster were overexpressed with a 4-fold and 3-fold increase in both GRWT and 380RWT, respectively. 205 
However, a similar trend was not observed for the H2-T6SS. Surprisingly, the T3SS showed decreased 206 
expression in DK17 for GRWT when compared to R (8-fold), but the opposite happens for DK41, where 207 
380RWT showed a 10-fold overexpression compared to 366. Considering that no differential expression was 208 
observed between R and G, and 366 and 380, this suggests that mutations in the retS-gacS-gacA-rsmA-209 
rsmYZ signaling pathway and the mutations outside of this system have an epigenetic effect.  210 
In GR and 380R, we also identified differential expression of some resistance-nodulation-cell division 211 
multidrug efflux pump operons. In GR, there was an 18-fold increased expression of mexXY (PA2018-2019), 212 
and a smaller 3-fold increase in 380R. The mexEF-oprN operon was also differentially expressed, but in the 213 
other direction. Here we observed a 5-fold decrease in GR and a 60-fold decrease in 380R.  214 
The next steps of residual evolution were contained in the subsequent strains (MRGWT and 364RGWT), where 215 
we have moved the retS and gacS of R and 366 into strains M and 364, respectively. In this case 95 genes 216 
were differentially expressed in both lineages with 68 in the same direction. Most of these genes were 217 
scattered through the genome and are either hypothetical proteins or tRNAs. MexCD were the only genes of 218 
note that are upregulated in both lineages with 65-fold in DK17 and just 3-fold in DK41.  219 
Combination effects of mutation 220 
An example of epigenetic effects was the two phenazine biosynthesis operons, phz1ABCDEFG and 221 
phz2ABCDEFG, that showed markedly different expression patterns in the two lineages when they were 222 
subject to retS-mutations and the residual evolution (Figure 2A). In RRM, the mutated retS gene lead to an 223 
increase of expression of 4-fold on average of both operons when compared with R (shown as RRM/R). 224 
However, when GRWT is compared with R (shown as GRWT/R) an increase of the phenazine biosynthesis 225 
operons WAS still observed with an average of 3-fold. This shows that the residual evolution was also in part 226 
responsible of the increased expression of phenazine biosynthesis operons even in absence of the effect 227 
related to a retS-mutation. Moreover, looking at the clinical isolate G, we observed a combined effect 228 
possibly due to both the mutated retS and the residual evolution; indeed, we observed an 8-fold over 229 
expression on average of both operons (shown as G/R). Therefore, we suggest the possibility of a 230 
combination effects of the retS-mutation and the residual evolution.   231 
Interestingly, in DK41 regarding the phenazine biosynthesis operons we observed an opposing trend in terms 232 
of expression contribution deriving from mutated retS and residual evolution (Figure 4B). Here, moving the 233 
mutation in retS into the ‘wild-type’ (366RM/366) resulted in an increase of expression of 6-fold on average 234 
for both phz operons, which is higher than what was seen in DK17. However, the genetic background of 235 
380RWT vs. 366 has the opposite effect of G vs. R. For 380RWT compared to 366, we observed an 8-fold 236 
decrease in expression of the phz1 and phz2 operons. Combining the mutation occurring in retS with the 237 
residual evolution, the clinical isolate, 380, we observed an expression profile of the phz1 and phz2 operons 238 
that was very similar to the clinical isolate, 366. In fact, the difference was not sizeable enough to be 239 
significantly different.  However, as above, the effects of the retS-mutation and the residual evolution seem 240 
to combine. 241 
Discussion 242 
The adaptation of P. aeruginosa to the CF airways is usually recognized as being driven by the loss of 243 
virulence factors with the concept being that this would render the bacteria capable of hiding from the 244 
immune system [38]. However, here we show that the picture may be more nuanced. Firstly, it appears that 245 
different secretion systems are needed at different time points during infection. The overexpression of H1-246 
T6SS and H2-T6SS suggests that these secretion systems are needed during the early stages of infection. 247 
However, later the second mutation in this system effectively switches off the expression of the T6SS and 248 
instead switches on the T3SS. Furthermore, we also observe that what appears to be signs of convergent 249 
evolution on a genomic level, may not necessarily lead to the same effects on a transcriptomic level.  250 
The changes in expression of the phz1 and phz2 operons exemplifies that while both lineages show similar 251 
mutations in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway from a purely genomic point of view, it is 252 
not possible to infer that these mutations will result in similar effects on a transcriptomic or phenotypic level. 253 
It appears that while mutating retS in the clinical isolates of R and 366 results in an increase of transcription 254 
of the phz1 and phz2 operons, the mutations that occur alongside the retS-mutation, pull the expression in 255 
opposite directions in these two lineages. This could mean that the evolution of P. aeruginosa in CF patients 256 
may show signs of convergence on a genomic level, but, in truth, the larger picture is more refined as an 257 
infecting lineage accumulates mutations in many genes that could have pleiotropic effects. The strains come 258 
from different lineages that have different genetic background (>10000 SNPs) [9], and it may be optimistic 259 
to expect that they would evolve and behave in the same manner. Furthermore, they were isolated from 260 
different patients, which only adds to the noise.  261 
The biological consequences of this differential expression of the phenazine biosynthesis operons for the 262 
infection of the CF airways are not known. It has previously been shown that pyocyanin is required for full 263 
virulence of P. aeruginosa and is thought to have a variety of effects, including defense against the host and 264 
functioning as a terminal electron acceptor for respiration [39], meaning that it can help P. aeruginosa 265 
survive under low-oxygen conditions [14], which can occur in the CF airways [40]. Furthermore, they 266 
negatively affect a number of eukaryotic processes including respiration and electron transport. 267 
It also appears that the mutations in retS, have a profound effect on the lifestyle of P. aeruginosa in general. 268 
The observation that transcript levels of rpoS increase in strains containing retS-mutations confirms this. It 269 
has been shown that biofilms of P. aeruginosa show increased expression of RpoS-activated transcripts [41] 270 
and that nutrient limited P. aeruginosa are highly tolerant to antibiotics [42]. This could suggest that this 271 
initial retS-mutation is a response to the antibiotic treatment pressure that P. aeruginosa experiences in the 272 
CF airways.  273 
This does not, however, explain why an apparent reversion in the retS-gacS-gacA-rsmA-rsmYZ signaling 274 
pathway occurs by mutations in gacS. This mutation switches P. aeruginosa into acute infection mode, 275 
which would seem to be unviable considering the supposed decreased antibiotic resistance caused by the 276 
retS-mutations mediated through increased expression of rpoS-related genes. A previous study by Sall, et al., 277 
[43], also observed a mutation in gacS in the P. aeruginosa strain, CHA. They found that this mutation 278 
lowered transcript levels of H1-T6SS and completely abolished protein production of the same. Additionally, 279 
they found increased expression of the T3SS and found that it was more virulent in a murine acute model of 280 
lung infection. If this is transferrable to P. aeruginosa infecting the CF airways, it could have detrimental 281 
effects on the patient. 282 
Conclusion 283 
In this study, we have examined 14 transcriptomes of six clinical isolates and eight strains of P. aeruginosa 284 
that were genetically engineered in the retS-gacS-gacA-rsmA-rsmYZ signaling pathway. We show that while 285 
similar mutations occur in regulatory systems, this does not mean that we can automatically infer that this 286 
will lead to similar transcriptomic or phenotypic effects. It appears that both the genetic background in which 287 
these mutations occur and their interplay with other mutations can have surprising effects on genes that may 288 
be of clinical importance in CF. This leads to the conclusion that for complex evolutionary patterns and 289 
systems, single mutation analysis may not be enough, that mutations have epigenetic effects on each other, 290 
and that the genetic background of a given strain plays a large role in differential gene expression. 291 
Materials and methods 292 
Strain handling 293 
Strains (Table 1) were grown at 37 °C in LB. Antibiotic concentrations: P. aeruginosa: 50 µg/mL for DK17-294 
derived strains and 200 µg/mL for DK41-derived strains.  E. coli: 10 µg/mL gentamicin for pEX19Gm 295 
constructs and 25 µg/mL kanamycin for E. coli/pRK2013. 296 
Genetic constructs 297 
Primers (Table 2) were designed to amplify approximately 800 bp of the desired gene with the desired 298 
mutation centered in the fragment using Phusion Hot Start II DNA polymerase with GC buffer. Fragments 299 
were gel-purified and cut with the appropriate restriction enzymes according to the manufacturer 300 
specifications. The vector, pEX19Gm, was also cut with the appropriate restriction enzymes and gel-purified. 301 
Ligation mixtures were set up in a ratio of 5:1 (insert:vector). Ligation occurred for an hour using T4 DNA 302 
ligase at room temperature resulting in plasmids in Table 3. Electrocompetent E. coli were 303 
electrotransformed with the ligation mixtures and incubated at 37 C for 1 hour and plated on LB plates 304 
containing 10 µg/mL gentamicin and left O/N at 37 C. The presence of the plasmid was confirmed by colony 305 
PCR.  306 
Allelic replacements 307 
Allelic replacements were made using triparental mating. Receptor, helper, donor strains were plated on LB 308 
plates containing the appropriate antibiotic and grown for 24-48 h, until an appropriate cell size was 309 
obtained. The receptor strains were incubated in 5 mL LB at 42 °C O/N in 50 mL falcon tubes, the helper 310 
strain was incubated in 5 mL LB O/N containing 25 µg/mL kanamycin at 30 °C, and donor strains were 311 
incubated in 2.5 mL LB containing 10 µg/mL gentamicin at 30 °C O/N. Receptor, help, and donor strains 312 
were mixed in a 3:1:1 ratio in a 1.5 mL Eppendorf tube and washed twice with 1 mL of LB with 313 
centrifugation at 6500 g for 2 min. The supernatant was discarded and the pellet was resuspended in the 314 
remaining supernatant. The pellets were spotted onto LB plates and left at 30 C for at least 6 hours. The 315 
mating drops were resuspended in LB and plated on LB plates containing an appropriate amount of 316 
gentamicin and incubated at 37 °C for 48 hours. Correct integration of the plasmid was checked using 317 
up_fwd/dw_rev and M13fwd/M13rev primers. Strains with integrated plasmids were then cultured O/N and 318 
plated on LB plates containing 10% sucrose. Strains were subjected to colony PCR, and correct strains were 319 
verified by sanger sequencing (Table 3).  320 
RNA-extraction 321 
Strains were grown in 50 mL LB in baffled shake flasks at 37 °C with shaking at 200 rpm at an initial 322 
concentration of OD600 = 0.01 and were harvested at OD600 = 1. A 10 mL volume of culture was added to 2 323 
mL of ice-cold STOP-solution (95% EtOH, 5% phenol), vortexed vigorously for 15 seconds, incubated at 324 
room temperature for 5 min, and vortexed for 5 min (7000 g, 4 °C). The pellet was resuspended in 1 mL of 325 
TRIzol® and stored at -80 °C until further use. RNA was extracted using Qiagen© RNeasy mini kits 326 
according to manufacturer instructions and the RNA integrity was checked on Agilent Bioanalyzer using the 327 
Agilent RNA 6000 Nano Kit. All experiments were conducted with biological duplicate samples. 328 
Data-handling 329 
Read quality was evaluated using FastQC [44]. The reads were mapped using Rockhopper to the genome of 330 
P. aeruginosa PAO1 and the raw count values were fed to T-REx [45], which uses EdgeR [46] to analyze the 331 
data. Normalization applied was weighted trimmed mean of M-values and genes with a low number of reads 332 
were filtered out. Further data handling was conducted in R  – statistical computing package [47] and 333 
Microsoft Excel. 334 
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Figures 475 
 476 
 477 
Figure 1A+B. The strategy behind the allelic replacements of retS and gacS. The timelines are not to scale. 478 
For both DK17 and DK41, we moved the mutated versions of retS and gacS into naïve clinical isolates that 479 
have not yet evolved mutations in these genes. This results in strains RRM (R with mutated retS), RRGM (R 480 
with mutated retS and gacS), 366RM (366 with mutated retS), and strain 366RGM (366 with mutated retS and 481 
gacS). Furthermore, we also moved the presumably functional versions of retS and gacS into the strains that 482 
evolved mutations in the same genes in the patients, resulting in strains GRWT, MRGWT, 380RWT, and 483 
364RGWT. 484 
 485 
 486 
 487 
Figure 2A+B. The log2-ratios of expression the phz2 (PA1899-1905) and phz1 (PA4210-4216) operons. All 488 
expressions are normalized to the lineages’ ‘wild-types’.  489 
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Tables 490 
Table 1. Strains used in this study. 491 
Strains Source Genotype 
R Clinical isolate MRCA 
G Clinical isolate retS 
M Clinical isolate retS, gacS 
366 Clinical isolate MRCA 
380 Clinical isolate retS 
364 Clinical isolate retS, gacS 
RRM Strain “R” with retS mutation from G retS 
RRGM Strain “R” with retS mutation from “G/M” and gacS mutation from 
“M” 
retS, gacS 
GRWT Strain “G” with retS from strain “R” retSWT 
MRGWT Strain “M” with retS and gacS from strain “R” retSWT, gacSWT 
366RM Strain “366” with retS mutation from strain “380” retS 
366RGM Strain “366” with retS mutation from “380/364” and gacS mutation 
from “364” 
retS, gacS 
380RWT Strain “380” with retS from strain “366” retSWT 
364RGWT Strain “364” with retS and gacS from strain “366” retSWT, gacSWT 
E. coli DH5α/pEX19Gm Cloning / donor  
E. coli/pRK2013 Helper in allelic replacements  
 492 
Table 2. Primers used in this study. Bold text signifies restriction enzyme site. 493 
Name Sequence (5’-3’) Purpose 
HindIII_retS_M_fwd ATATAAGCTTGGCACCAAGCAACTCGAT Cloning 
EcoRI_retS_M_rev ATATGAATTCCAGGTTTCGTTGTCGTCCA Cloning 
retS_M_up_fwd GTGTTCCTGCCGGTACTGTT Validation 
retS_M_dw_rev ACTGCTGCACCAGCACCTT Validation 
HindIII_gacS_M_fwd ATATAAGCTTCAGTTCGTCCAGCTCGTTG Cloning 
EcoRI_gacS_M_rev ATATGAATTCCTTCGTCGCAAGCCGAAT Cloning 
gacS_M_up_fwd GTTGTGCTGCATTTCCTCCT Validation 
gacS_M_dw_rev CAATCGTGCCAGTATTCACG Validation 
HindIII_retS_364_fwd ATATAAGCTTCTCGCGCTCCTACCTGTTCT Cloning 
EcoRI_retS_364_rev ATATGAATTCAGGAACTCGGCCTTGGTCT Cloning 
retS_364_up_fwd CGGGTGCAGTACCTGGACTA Validation 
retS_364_dw_rev GATCTCGTGGCTGATCTTGG Validation 
HindIII_gacS_364_fwd2 ATATAAGCTTGTGGTGCGACAGTTCCAGTT Cloning 
EcoRI_gacS_364_rev2 ATATGAATTCCGGAGTTGGCGAAGAATCTC Cloning 
gacS_364_up_fwd2 ATCAGCAAGAGGCTGGTGAA Validation 
gacS_364_dw_rev2 AGGGCTGACATCAGGATCAC Validation 
M13fwd GTAAAACGACGGCCAG Validation 
M13rev CAGGAAACAGCTATGAC Validation 
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Table 3. Plasmids used in this study 495 
Name Relevant features 
pEX19Gm Gmr, oriT, sacB, MCS 
pEX19Gm∷retSDK17 800bp fragment of mutated retS from DK17, Gmr, oriT, sacB, MCS 
pEX19Gm∷retSDK41 800bp fragment of mutated retS from DK41, Gmr, oriT, sacB, MCS 
pEX19Gm∷retSDK17WT 800bp fragment of wildtype retS from DK17, Gmr, oriT, sacB, MCS 
pEX19Gm∷retSDK41WT 800bp fragment of wildtype retS from DK17, Gmr, oriT, sacB, MCS 
pEX19Gm∷gacSDK17 800bp fragment of mutated gacS from DK17, Gmr, oriT, sacB, MCS 
pEX19Gm∷gacSDK41 800bp fragment of mutated gacS from DK41, Gmr, oriT, sacB, MCS 
pEX19Gm∷gacSDK17WT 800bp fragment of wildtype gacS from DK17, Gmr, oriT, sacB, MCS 
pEX19Gm∷gacSDK41WT 800bp fragment of wildtype gacS from DK41, Gmr, oriT, sacB, MCS 
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